171 results on '"Robert W. Doms"'
Search Results
2. Platelet Factor 4 Inhibits and Enhances HIV-1 Infection in a Concentration-Dependent Manner by Modulating Viral Attachment
- Author
-
Zahra F. Parker, Douglas B. Cines, Amber M. Riblett, Mortimer Poncz, Fang-Hua Lee, Bruce S. Sachais, Lubica Rauova, Ann H. Rux, and Robert W. Doms
- Subjects
0301 basic medicine ,Immunology ,Cell ,Virus Attachment ,Plasma protein binding ,Biology ,Platelet Factor 4 ,Virus ,Glycosaminoglycan ,03 medical and health sciences ,0302 clinical medicine ,Viral envelope ,Virology ,medicine ,Humans ,env Gene Products, Human Immunodeficiency Virus ,In vitro ,Cell biology ,030104 developmental biology ,Infectious Diseases ,medicine.anatomical_structure ,Biochemistry ,Host-Pathogen Interactions ,HIV-1 ,Bone marrow ,Platelet factor 4 ,Protein Binding ,030215 immunology - Abstract
Platelet factor 4 (PF4) has been recently shown to inhibit infection by a broad range of human immunodeficiency virus type 1 (HIV-1) isolates in vitro. We found that the inhibitory effects of PF4 are limited to a defined concentration range where PF4 exists largely in a monomeric state. Under these conditions, PF4 bound the HIV-1 envelope protein and inhibited HIV-1 attachment to the cell surface. However, as concentrations increased to the point where PF4 exists largely in tetrameric or higher-order forms, viral infection in vitro was enhanced. Enhancement could be inhibited by mutations in PF4 that shift the oligomeric equilibrium toward the monomeric state, or by using soluble glycosaminoglycans (GAGs) to which tetrameric PF4 avidly binds. We conclude that at physiologically relevant concentrations, oligomeric PF4 enhances infection by HIV-1 by interacting with the viral envelope protein as well as cell surface GAGs, enhancing virus attachment to the cell surface. This effect was not specific to HIV-1, as enhancement was seen with some but not all other viruses tested. The biphasic effects of PF4 on HIV-1 infection suggest that native PF4 will not be a useful antiviral agent and that PF4 could contribute to the hematologic abnormalities commonly seen in HIV-infected individuals by enhancing virus infection in the bone marrow.
- Published
- 2016
3. What Came First—the Virus or the Egg?
- Author
-
Robert W. Doms
- Subjects
0301 basic medicine ,biology ,biology.organism_classification ,medicine.disease ,Virology ,Fusion protein ,General Biochemistry, Genetics and Molecular Biology ,Virus ,Transmembrane protein ,Zika virus ,Dengue fever ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,medicine ,Gamete ,Gene ,030217 neurology & neurosurgery - Abstract
Three recent studies find that the single-pass transmembrane protein HAP2 mediates gamete fusion and is remarkably similar to class II fusion proteins found in viruses such as dengue and Zika.
- Published
- 2017
4. Gene Therapy Targeting HIV Entry
- Author
-
Chuka A. Didigu and Robert W. Doms
- Subjects
HIV entry ,Oncology ,medicine.medical_specialty ,Chemokine receptor CCR5 ,medicine.medical_treatment ,Genetic enhancement ,lcsh:QR1-502 ,Human immunodeficiency virus (HIV) ,HIV Infections ,Review ,Hematopoietic stem cell transplantation ,medicine.disease_cause ,HIV reservoir ,lcsh:Microbiology ,Virology ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,biology ,business.industry ,HIV cure ,Hematopoietic Stem Cell Transplantation ,HIV ,virus diseases ,Genetic Therapy ,Virus Internalization ,CCR5 delta 32 ,gene therapy ,Transplantation ,Infectious Diseases ,Allogeneic hsct ,Host-Pathogen Interactions ,Immunology ,biology.protein ,Allogeneic hematopoietic stem cell transplant ,Stem cell ,business - Abstract
Despite the unquestionable success of antiretroviral therapy (ART) in the treatment of HIV infection, the cost, need for daily adherence, and HIV-associated morbidities that persist despite ART all underscore the need to develop a cure for HIV. The cure achieved following an allogeneic hematopoietic stem cell transplant (HSCT) using HIV-resistant cells, and more recently, the report of short-term but sustained, ART-free control of HIV replication following allogeneic HSCT, using HIV susceptible cells, have served to both reignite interest in HIV cure research, and suggest potential mechanisms for a cure. In this review, we highlight some of the obstacles facing HIV cure research today, and explore the roles of gene therapy targeting HIV entry, and allogeneic stem cell transplantation in the development of strategies to cure HIV infection.
- Published
- 2014
5. Phenotypic properties of transmitted founder HIV-1
- Author
-
Beatrice H. Hahn, Lara Zajic, Bhavna Hora, George M. Shaw, Julie M. Decker, Amit Kumar, Haitao Ding, Jennifer Hopper, Christina Ochsenbauer, Anthony P. West, Robert W. Doms, John C. Kappes, Feng Gao, Shilpa S. Iyer, Thomas N. Denny, Barton F. Haynes, Mark Muldoon, Nina Bhardwaj, Hannah J. Barbian, Hui Li, Nicholas F. Parrish, James Theiler, Fangping Cai, Erica H. Parrish, Elena E. Giorgi, Anna Berg, Persephone Borrow, Pamela J. Bjorkman, Bette T. Korber, Craig B. Wilen, Meagan O’Brien, and Rachel P. Galimidi
- Subjects
CD4-Positive T-Lymphocytes ,viruses ,Molecular Sequence Data ,Enzyme-Linked Immunosorbent Assay ,HIV Infections ,Biology ,Chemokine receptor ,Viral Envelope Proteins ,Humans ,Cloning, Molecular ,Tropism ,Infectivity ,Multidisciplinary ,Innate immune system ,Base Sequence ,Virion ,Dendritic Cells ,Sequence Analysis, DNA ,Dendritic cell ,Biological Sciences ,AIDS Vaccines ,Phenotype ,Virology ,Titer ,HIV-1 ,Linear Models - Abstract
Defining the virus–host interactions responsible for HIV-1 transmission, including the phenotypic requirements of viruses capable of establishing de novo infections, could be important for AIDS vaccine development. Previous analyses have failed to identify phenotypic properties other than chemokine receptor 5 (CCR5) and CD4+ T-cell tropism that are preferentially associated with viral transmission. However, most of these studies were limited to examining envelope (Env) function in the context of pseudoviruses. Here, we generated infectious molecular clones of transmitted founder (TF; n = 27) and chronic control (CC; n = 14) viruses of subtypes B ( n = 18) and C ( n = 23) and compared their phenotypic properties in assays specifically designed to probe the earliest stages of HIV-1 infection. We found that TF virions were 1.7-fold more infectious ( P = 0.049) and contained 1.9-fold more Env per particle ( P = 0.048) compared with CC viruses. TF viruses were also captured by monocyte-derived dendritic cells 1.7-fold more efficiently ( P = 0.035) and more readily transferred to CD4+ T cells ( P = 0.025). In primary CD4+ T cells, TF and CC viruses replicated with comparable kinetics; however, when propagated in the presence of IFN-α, TF viruses replicated to higher titers than CC viruses. This difference was significant for subtype B ( P = 0.000013) but not subtype C ( P = 0.53) viruses, possibly reflecting demographic differences of the respective patient cohorts. Together, these data indicate that TF viruses are enriched for higher Env content, enhanced cell-free infectivity, improved dendritic cell interaction, and relative IFN-α resistance. These viral properties, which likely act in concert, should be considered in the development and testing of AIDS vaccines.
- Published
- 2013
6. Transmitted/Founder and Chronic HIV-1 Envelope Proteins Are Distinguished by Differential Utilization of CCR5
- Author
-
Benhur Lee, Craig B. Wilen, Fang-Hua Lee, Zahra F. Parker, Chukwuka A. Didigu, Shilpa S. Iyer, John P. Moore, Per Johan Klasse, Beatrice H. Hahn, Robert W. Doms, Kelechi Chikere, Reem Berro, George M. Shaw, and Nicholas F. Parrish
- Subjects
CD4-Positive T-Lymphocytes ,Receptors, CCR5 ,viruses ,Immunology ,Virus Attachment ,HIV Infections ,CCR5 receptor antagonist ,Biology ,Hiv 1 envelope ,Microbiology ,Virus ,Cell Line ,Maraviroc ,chemistry.chemical_compound ,Cyclohexanes ,Virology ,Humans ,chemistry.chemical_classification ,HEK 293 cells ,env Gene Products, Human Immunodeficiency Virus ,virus diseases ,Triazoles ,Virus Internalization ,Phenotype ,Virus-Cell Interactions ,HEK293 Cells ,chemistry ,Cell culture ,Insect Science ,CCR5 Receptor Antagonists ,HIV-1 ,Glycoprotein - Abstract
Infection by HIV-1 most often results from the successful transmission and propagation of a single virus variant, termed the transmitted/founder (T/F) virus. Here, we compared the attachment and entry properties of envelope (Env) glycoproteins from T/F and chronic control (CC) viruses. Using a panel of 40 T/F and 47 CC Envs, all derived by single genome amplification, we found that 52% of clade C and B CC Envs exhibited partial resistance to the CCR5 antagonist maraviroc (MVC) on cells expressing high levels of CCR5, while only 15% of T/F Envs exhibited this same property. Moreover, subtle differences in the magnitude with which MVC inhibited infection on cells expressing low levels of CCR5, including primary CD4 + T cells, were highly predictive of MVC resistance when CCR5 expression levels were high. These results are consistent with previous observations showing a greater sensitivity of T/F Envs to MVC inhibition on cells expressing very high levels of CCR5 and indicate that CC Envs are often capable of recognizing MVC-bound CCR5, albeit inefficiently on cells expressing physiologic levels of CCR5. When CCR5 expression levels are high, this phenotype becomes readily detectable. The utilization of drug-bound CCR5 conformations by many CC Envs was seen with other CCR5 antagonists, with replication-competent viruses, and did not obviously correlate with other phenotypic traits. The striking ability of clade C and B CC Envs to use MVC-bound CCR5 relative to T/F Envs argues that the more promiscuous use of CCR5 by these Env proteins is selected against at the level of virus transmission and is selected for during chronic infection.
- Published
- 2013
7. Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques
- Author
-
Gerald H. Learn, Brandon F. Keele, Xingpei Hao, Jason Gorman, Sampa Santra, Ben Policicchio, Jeffrey D. Lifson, Barton F. Haynes, Claire Deleage, Hui Li, Gwo-Yu Chuang, Georgia D. Tomaras, Xiaoying Shen, Ivona Pandrea, Jacob D. Estes, Wenge Ding, Paul Hahn, George M. Shaw, Shuyi Wang, Hua-Xin Liao, Beatrice H. Hahn, Peter Kwong, Cristian Apetrei, Theodora Hatziioannou, Eunlim Kim, Robert W. Doms, Michael Farzan, Zahra F. Parker, Rui Kong, Egidio Brocca-Cofano, Fang Hua Lee, David C. Montefiori, Mark G. Lewis, Matthew R. Gardner, Joseph Sodroski, S. Munir Alam, and Elena Chertova
- Subjects
0301 basic medicine ,Antigenicity ,viruses ,030106 microbiology ,Mutation, Missense ,Simian Acquired Immunodeficiency Syndrome ,HIV Infections ,medicine.disease_cause ,Virus Replication ,Neutralization ,03 medical and health sciences ,Viral entry ,medicine ,Animals ,Humans ,Neutralizing antibody ,Immunodeficiency ,Multidisciplinary ,biology ,env Gene Products, Human Immunodeficiency Virus ,virus diseases ,Simian immunodeficiency virus ,medicine.disease ,Virology ,Macaca mulatta ,030104 developmental biology ,Viral replication ,PNAS Plus ,Amino Acid Substitution ,CD4 Antigens ,biology.protein ,HIV-1 ,Simian Immunodeficiency Virus ,Antibody - Abstract
Most simian-human immunodeficiency viruses (SHIVs) bearing envelope (Env) glycoproteins from primary HIV-1 strains fail to infect rhesus macaques (RMs). We hypothesized that inefficient Env binding to rhesus CD4 (rhCD4) limits virus entry and replication and could be enhanced by substituting naturally occurring simian immunodeficiency virus Env residues at position 375, which resides at a critical location in the CD4-binding pocket and is under strong positive evolutionary pressure across the broad spectrum of primate lentiviruses. SHIVs containing primary or transmitted/founder HIV-1 subtype A, B, C, or D Envs with genotypic variants at residue 375 were constructed and analyzed in vitro and in vivo. Bulky hydrophobic or basic amino acids substituted for serine-375 enhanced Env affinity for rhCD4, virus entry into cells bearing rhCD4, and virus replication in primary rhCD4 T cells without appreciably affecting antigenicity or antibody-mediated neutralization sensitivity. Twenty-four RMs inoculated with subtype A, B, C, or D SHIVs all became productively infected with different Env375 variants-S, M, Y, H, W, or F-that were differentially selected in different Env backbones. Notably, SHIVs replicated persistently at titers comparable to HIV-1 in humans and elicited autologous neutralizing antibody responses typical of HIV-1. Seven animals succumbed to AIDS. These findings identify Env-rhCD4 binding as a critical determinant for productive SHIV infection in RMs and validate a novel and generalizable strategy for constructing SHIVs with Env glycoproteins of interest, including those that in humans elicit broadly neutralizing antibodies or bind particular Ig germ-line B-cell receptors.
- Published
- 2016
8. Efficient production of Hantaan and Puumala pseudovirions for viral tropism and neutralization studies
- Author
-
Josiah Petersen, Jay W. Hooper, Robert W. Doms, and Meda M. Higa
- Subjects
Virus Cultivation ,Bunyaviridae ,viruses ,Biology ,Antibodies, Viral ,Puumala virus ,Cell Line ,Mice ,Virus entry ,03 medical and health sciences ,0302 clinical medicine ,Pseudovirion ,Neutralization Tests ,Viral entry ,Virology ,Animals ,Humans ,Tropism ,Puumala ,030304 developmental biology ,Hantavirus ,Infectivity ,0303 health sciences ,virus diseases ,Pseudovirions ,biology.organism_classification ,Hantaan virus ,3. Good health ,Viral Tropism ,Vesicular stomatitis virus ,Hemorrhagic Fever with Renal Syndrome ,Tissue tropism ,Glycoprotein ,Hantaan ,030215 immunology - Abstract
Puumala (PUUV) and Hantaan (HTNV) viruses are hantaviruses within the family Bunyaviridae and associated with Hemorrhagic Fever with Renal Syndrome (HFRS) in humans. Little is known about how these viruses interact with host cells, though pathogenic hantaviruses interact with α v β 3 integrin. To study host cell interactions and rapidly test the ability of antibodies to prevent infection, we produced HTNV and PUUV pseudovirions on a vesicular stomatitis virus (VSV) core. Similar to replication-competent hantaviruses, infection was low-pH-dependent. Despite broad cell tropism, several human T cell lines were poorly permissive to hantavirus pseudovirions, compared to VSV, indicating a relative block to infection at the level of entry. Stable expression of α v β 3 integrin in SupT1 cells did not restore infectivity. Finally, the pseudovirion system provided a rapid, quantitative, and specific method to screen for neutralizing antibodies in immune sera.
- Published
- 2012
9. Novel Approaches to Inhibit HIV Entry
- Author
-
Chukwuka A. Didigu and Robert W. Doms
- Subjects
HIV entry ,medicine.medical_treatment ,Genetic enhancement ,viruses ,Human immunodeficiency virus (HIV) ,lcsh:QR1-502 ,HIV Infections ,Review ,Biology ,medicine.disease_cause ,CXCR4 ,Models, Biological ,lcsh:Microbiology ,Pharmacotherapy ,Drug Therapy ,Virology ,medicine ,Humans ,Receptor ,Gene ,Hematopoietic stem cell ,HIV ,virus diseases ,Immunotherapy ,Genetic Therapy ,Virus Internalization ,gene therapy ,Infectious Diseases ,medicine.anatomical_structure ,Immunology ,CCR5 - Abstract
Human Immunodeficiency Virus (HIV) entry into target cells is a multi-step process involving binding of the viral glycoprotein, Env, to its receptor CD4 and a coreceptor—either CCR5 or CXCR4. Understanding the means by which HIV enters cells has led to the identification of genetic polymorphisms, such as the 32 base-pair deletion in the ccr5 gene (ccr5∆32) that confers resistance to infection in homozygous individuals, and has also resulted in the development of entry inhibitors—small molecule antagonists that block infection at the entry step. The recent demonstration of long-term control of HIV infection in a leukemic patient following a hematopoietic stem cell transplant using cells from a ccr5∆32 homozygous donor highlights the important role of the HIV entry in maintaining an established infection and has led to a number of attempts to treat HIV infection by genetically modifying the ccr5 gene. In this review, we describe the HIV entry process and provide an overview of the different classes of approved HIV entry inhibitors while highlighting novel genetic strategies aimed at blocking HIV infection at the level of entry.
- Published
- 2012
10. Primary Infection by a Human Immunodeficiency Virus with Atypical Coreceptor Tropism
- Author
-
Julie M. Decker, Elizabeth A. Henning, Beatrice H. Hahn, Robert W. Doms, Barton F. Haynes, Rebecca Nedellec, Hui Li, Yi Chen, Jennifer M. Pfaff, M. A. Moody, Hongshuo Song, John C. Tilton, Craig B. Wilen, Mark S. Drinker, George M. Shaw, Robert J. Schutte, Donald E. Mosier, Xusheng Lü, Anna Berg, Feng Gao, Chunlai Jiang, Stephanie A. Freel, Jeffrey W. Pavlicek, Nicholas F. Parrish, and Georgia D. Tomaras
- Subjects
CD4-Positive T-Lymphocytes ,Receptors, Peptide ,viruses ,Amino Acid Motifs ,Immunology ,Gene Expression ,Biology ,Microbiology ,Virus ,Receptors, G-Protein-Coupled ,Receptors, HIV ,Virology ,Humans ,Antibody-dependent enhancement ,Receptors, Lipoxin ,Cells, Cultured ,Infectivity ,chemistry.chemical_classification ,Apelin Receptors ,Macrophages ,env Gene Products, Human Immunodeficiency Virus ,virus diseases ,RNA ,Receptors, Formyl Peptide ,In vitro ,Viral Tropism ,Amino Acid Substitution ,Genetic Diversity and Evolution ,chemistry ,Cell culture ,Insect Science ,HIV-1 ,Tissue tropism ,Glycoprotein - Abstract
The great majority of human immunodeficiency virus type 1 (HIV-1) strains enter CD4 + target cells by interacting with one of two coreceptors, CCR5 or CXCR4. Here we describe a transmitted/founder (T/F) virus (ZP6248) that was profoundly impaired in its ability to utilize CCR5 and CXCR4 coreceptors on multiple CD4 + cell lines as well as primary human CD4 + T cells and macrophages in vitro yet replicated to very high titers (>80 million RNA copies/ml) in an acutely infected individual. Interestingly, the envelope (Env) glycoprotein of this clade B virus had a rare GPEK sequence in the crown of its third variable loop (V3) rather than the consensus GPGR sequence. Extensive sequencing of sequential plasma samples showed that the GPEK sequence was present in virtually all Envs, including those from the earliest time points after infection. The molecularly cloned (single) T/F virus was able to replicate, albeit poorly, in cells obtained from ccr5 Δ32 homozygous donors. The ZP6248 T/F virus could also infect cell lines overexpressing the alternative coreceptors GPR15, APJ, and FPRL-1. A single mutation in the V3 crown sequence (GPEK->GPGK) of ZP6248 restored its infectivity in CCR5 + cells but reduced its ability to replicate in GPR15 + cells, indicating that the V3 crown motif played an important role in usage of this alternative coreceptor. These results suggest that the ZP6248 T/F virus established an acute in vivo infection by using coreceptor(s) other than CCR5 or CXCR4 or that the CCR5 coreceptor existed in an unusual conformation in this individual.
- Published
- 2011
11. Phenotypic and Immunologic Comparison of Clade B Transmitted/Founder and Chronic HIV-1 Envelope Glycoproteins
- Author
-
George M. Shaw, Jennifer M. Pfaff, John C. Tilton, Jason A. Wojcechowskyj, Josiah Petersen, Hillel Haim, Julie M. Decker, Nicholas F. Parrish, Robert W. Doms, David C. Montefiori, Craig B. Wilen, Joseph Sodroski, Beatrice H. Hahn, Elizabeth A. Henning, and Barton F. Haynes
- Subjects
CD4-Positive T-Lymphocytes ,Male ,Sexual transmission ,viruses ,Immunology ,HIV Infections ,HIV Antibodies ,Microbiology ,Virus ,Virology ,Humans ,Tropism ,Infectivity ,Genetics ,biology ,env Gene Products, Human Immunodeficiency Virus ,virus diseases ,Dendritic Cells ,Dendritic cell ,Virus Internalization ,Antibodies, Neutralizing ,Viral Tropism ,Insect Science ,HIV-1 ,Tissue tropism ,Pseudotyping ,biology.protein ,Pathogenesis and Immunity ,Female ,Antibody - Abstract
Sexual transmission of human immunodeficiency virus type 1 (HIV-1) across mucosal barriers is responsible for the vast majority of new infections. This relatively inefficient process results in the transmission of a single transmitted/founder (T/F) virus, from a diverse viral swarm in the donor, in approximately 80% of cases. Here we compared the biological activities of 24 clade B T/F envelopes (Envs) with those from 17 chronic controls to determine whether the genetic bottleneck that occurs during transmission is linked to a particular Env phenotype. To maximize the likelihood of an intact mucosal barrier in the recipients and to enhance the sensitivity of detecting phenotypic differences, only T/F Envs from individuals infected with a single T/F variant were selected. Using pseudotyping to assess Env function in single-round infectivity assays, we compared coreceptor tropism, CCR5 utilization efficiencies, primary CD4 + T cell subset tropism, dendritic cell trans -infections, fusion kinetics, and neutralization sensitivities. T/F and chronic Envs were phenotypically equivalent in most assays; however, T/F Envs were modestly more sensitive to CD4 binding site antibodies b12 and VRC01, as well as pooled human HIV Ig. This finding was independently validated with a panel of 14 additional chronic HIV-1 Env controls. Moreover, the enhanced neutralization sensitivity was associated with more efficient binding of b12 and VRC01 to T/F Env trimers. These data suggest that there are subtle but significant structural differences between T/F and chronic clade B Envs that may have implications for HIV-1 transmission and the design of effective vaccines.
- Published
- 2011
12. HIV-1 Resistance to CCR5 Antagonists Associated with Highly Efficient Use of CCR5 and Altered Tropism on Primary CD4 + T Cells
- Author
-
Jennifer M. Pfaff, Robert W. Doms, Craig B. Wilen, Benhur Lee, James F. Demarest, Jessamina E. Harrison, and John C. Tilton
- Subjects
CD4-Positive T-Lymphocytes ,Receptors, CCR5 ,Anti-HIV Agents ,viruses ,Immunology ,Mutation, Missense ,Virus Attachment ,Diketopiperazines ,Viral quasispecies ,CCR5 receptor antagonist ,HIV Envelope Protein gp120 ,Biology ,V3 loop ,Gp41 ,Benzoates ,Microbiology ,Piperazines ,Virus ,Receptors, HIV ,Immune system ,Virology ,Drug Resistance, Viral ,Vaccines and Antiviral Agents ,Humans ,Spiro Compounds ,Tropism ,virus diseases ,HIV Envelope Protein gp41 ,Viral Tropism ,Insect Science ,CCR5 Receptor Antagonists ,HIV-1 ,Tissue tropism - Abstract
We previously reported on a panel of HIV-1 clade B envelope (Env) proteins isolated from a patient treated with the CCR5 antagonist aplaviroc (APL) that were drug resistant. These Envs used the APL-bound conformation of CCR5, were cross resistant to other small-molecule CCR5 antagonists, and were isolated from the patient's pretreatment viral quasispecies as well as after therapy. We analyzed viral and host determinants of resistance and their effects on viral tropism on primary CD4 + T cells. The V3 loop contained residues essential for viral resistance to APL, while additional mutations in gp120 and gp41 modulated the magnitude of drug resistance. However, these mutations were context dependent, being unable to confer resistance when introduced into a heterologous virus. The resistant virus displayed altered binding between gp120 and CCR5 such that the virus became critically dependent on the N′ terminus of CCR5 in the presence of APL. In addition, the drug-resistant Envs studied here utilized CCR5 very efficiently: robust virus infection occurred even when very low levels of CCR5 were expressed. However, recognition of drug-bound CCR5 was less efficient, resulting in a tropism shift toward effector memory cells upon infection of primary CD4 + T cells in the presence of APL, with relative sparing of the central memory CD4 + T cell subset. If such a tropism shift proves to be a common feature of CCR5-antagonist-resistant viruses, then continued use of CCR5 antagonists even in the face of virologic failure could provide a relative degree of protection to the T CM subset of CD4 + T cells and result in improved T cell homeostasis and immune function.
- Published
- 2010
13. HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide
- Author
-
Leslie A. Blackburn, Neelanjana Ray, and Robert W. Doms
- Subjects
Models, Molecular ,Enfuvirtide ,Anti-HIV Agents ,Immunology ,Mutant ,Context (language use) ,HIV Antibodies ,Biology ,medicine.disease_cause ,Gp41 ,Microbiology ,Virus ,Cell Line ,Suppression, Genetic ,Viral envelope ,Neutralization Tests ,Virology ,Drug Resistance, Viral ,medicine ,Humans ,Mutation ,Virus Internalization ,HIV Envelope Protein gp41 ,Peptide Fragments ,Insect Science ,HIV-1 ,biology.protein ,Antibody ,medicine.drug - Abstract
Enfuvirtide (ENF) prevents the entry of human immunodeficiency virus type 1 (HIV-1) into cells by binding to the HR-1 region of the viral envelope (Env) protein gp41 subunit. Resistance to ENF arises via mutations in the drug binding site in HR-1. In addition, HR-2 mutations are commonly observed in ENF-resistant Env proteins, though their role remains unclear. We explored the mechanistic basis for clinical resistance to ENF and the role of HR-2 mutations. Using panels of ENF resistance-associated mutants for two patients, we found that mutations in HR-1 slowed the fusion kinetics and that mutations in HR-2 restored fusion rates. We assessed the differences in the rates of fusion of these mutants from a temperature-arrested state and observed similar trends, suggesting that the step of delay occurs after coreceptor engagement. Sensitivity to neutralizing antibodies was unchanged by the HR-1 and HR-2 mutants in each panel. Since this result was in contrast to those of a previous in vitro analysis where enhanced sensitivity to neutralization was demonstrated for heterologous Envs with ENF resistance-associated HR-1 changes, we examined the context dependence of HR-1 and HR-2 mutations by transferring the mutations seen in one patient into the Env context of another. These studies revealed that some, but not all, HR-1 mutations, when placed out of context (i.e., in a patient Env where they did not originally arise), enhance sensitivity to neutralizing antibodies. However, in most cases, HR-1 mutations in ENF-treated patients evolve in a manner that preserves pretreatment neutralization sensitivity so as to evade the pressures of the immune system.
- Published
- 2009
14. Baseline Resistance of Primary Human Immunodeficiency Virus Type 1 Strains to the CXCR4 Inhibitor AMD3100
- Author
-
Luz-Jeannette Sierra, Jonathan B. Lynch, Leslie A. Blackburn, Neelanjana Ray, Ronald G. Collman, Jessamina E. Harrison, and Robert W. Doms
- Subjects
Benzylamines ,Receptors, CXCR4 ,CXCR4 Inhibitor ,Receptors, CCR5 ,viruses ,Immunology ,Heterologous ,HIV Envelope Protein gp120 ,Cyclams ,Quail ,Microbiology ,Virus ,Viral envelope ,HIV Fusion Inhibitors ,Heterocyclic Compounds ,Virology ,Drug Resistance, Viral ,Vaccines and Antiviral Agents ,Animals ,Cells, Cultured ,CXCR4 antagonist ,biology ,biology.organism_classification ,Resistance mutation ,Insect Science ,Lentivirus ,HIV-1 ,Viral disease - Abstract
We screened a panel of R5X4 and X4 human immunodeficiency virus type 1 (HIV-1) strains for their sensitivities to AMD3100, a small-molecule CXCR4 antagonist that blocks HIV-1 infection via this coreceptor. While no longer under clinical development, AMD3100 is a useful tool with which to probe interactions between the viral envelope (Env) protein and CXCR4 and to identify pathways by which HIV-1 may become resistant to this class of antiviral agents. While infection by most virus strains was completely blocked by AMD3100, we identified several R5X4 and X4 isolates that exhibited plateau effects: as the AMD3100 concentration was increased, virus infection and membrane fusion diminished to variable degrees. Once saturating concentrations of AMD3100 were achieved, further inhibition was not observed, indicating a noncompetitive mode of viral resistance to the drug. The magnitude of the plateau varied depending on the virus isolate, as well as the cell type used, with considerable variation observed when primary human T cells from different human donors were used. Structure-function studies indicated that the V1/V2 region of the R5X4 HIV-1 isolate DH12 was necessary for AMD3100 resistance and could confer this property on two heterologous Env proteins. We conclude that some R5X4 and X4 HIV-1 isolates can utilize the AMD3100-bound conformation of CXCR4, with the efficiency being influenced by both viral and host factors. Baseline resistance to this CXCR4 antagonist could influence the clinical use of such compounds.
- Published
- 2008
15. An Engineered Saccharomyces cerevisiae Strain Binds the Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody 2G12 and Elicits Mannose-Specific gp120-Binding Antibodies
- Author
-
Karen K. Cai, Hu Fu, Robert W. Doms, Jianqiao Lin, Fang-Hua Lee, Robert J. Luallen, Yu Geng, David C. Montefiori, Caroline Agrawal, Innocent Mboudjeka, and David F. Smith
- Subjects
Glycan ,Glycosylation ,Blotting, Western ,Molecular Sequence Data ,Immunology ,Mutant ,Saccharomyces cerevisiae ,Mannose ,Enzyme-Linked Immunosorbent Assay ,HIV Antibodies ,HIV Envelope Protein gp120 ,Antibodies, Viral ,Microbiology ,Epitope ,chemistry.chemical_compound ,symbols.namesake ,Virology ,Vaccines and Antiviral Agents ,Immunoprecipitation ,Amino Acid Sequence ,chemistry.chemical_classification ,biology ,Immune Sera ,virus diseases ,Antibodies, Monoclonal ,Golgi apparatus ,biology.organism_classification ,Molecular biology ,Microscopy, Fluorescence ,chemistry ,Biochemistry ,Insect Science ,HIV-1 ,biology.protein ,symbols ,Genetic Engineering ,Glycoprotein ,Broadly Neutralizing Antibodies - Abstract
The development of a human immunodeficiency virus (HIV) vaccine able to induce neutralizing antibodies against a broad spectrum of primary isolates is complicated by the large diversity of HIV type 1 (HIV-1) strains, the continual mutation of the envelope (Env) glycoprotein in the face of immune selective pressure, and the presence of numerous N-linked glycans that mask polypeptide epitopes (7). Indeed, genetic deletion of N-linked carbohydrate sites can greatly increase the sensitivity of HIV-1 to antibody-mediated neutralization (3, 12, 25, 26, 34, 35). One of the few broadly neutralizing monoclonal antibodies (MAbs) isolated from HIV-1-infected patients, 2G12, circumvents these obstacles by binding to relatively conserved high-mannose-type oligosaccharides exposed on the glycan shield of the gp120 subunit of Env (47, 49, 54). The 2G12 epitope consists of an array of at least three such glycans presented as a dense cluster of terminal mannose sugars (49, 54). Crystal structures of the 2G12 Fab in complex with carbohydrates reveal a specificity toward Manα1,2Man disaccharides, alone or terminally exposed on the D1 and D3 arms of Man9GlcNAc2 (Man9) and Man8GlcNAc2 (Man8) structures, without recognizing other mannose disaccharides, including Manα1,3Man and Manα1,6Man (8, 9). The relatively conserved nature of the 2G12 epitope and the role of N-linked carbohydrates in protecting HIV-1 from antibodies make the glycan shield of Env a viable vaccine target (46, 48). The gp120 subunit of the HIV-1 Env protein contains an average of 25 N-linked glycosylation sites, approximately half of which are composed of high-mannose or hybrid-type glycans (13, 31, 59). To mimic the 2G12 epitope, glycoantigens have been constructed by several laboratories through chemical synthesis of mannose oligosaccharides and chemoenzymatic conjugation to different scaffolds (8, 9, 27, 29, 41, 56). However, to our knowledge, these approaches have yet to elicit antibodies that cross-react with gp120 or neutralize the virus. An alternative approach is to identify and produce other proteins that contain carbohydrate structures similar to those comprising the 2G12 epitope on HIV-1 Env. Analysis of the Saccharomyces cerevisiae genome reveals the presence of numerous proteins that contain a large number of potential N-linked glycosylation sites, making yeast a possible source of proteins with closely arrayed N-linked glycans with the potential to cross-react with the 2G12 antibody. However, while essentially identical high-mannose core structures are added to the N-linked glycosylation sites on both yeast and mammalian cell proteins in the endoplasmic reticulum (ER) (4, 14, 18, 23), subsequent carbohydrate processing pathways in the Golgi apparatus diverge significantly. In yeast cells, numerous mannose residues are added to the core structure in the Golgi apparatus, forming polymannose-type glycans (14). Over a dozen proteins in the Golgi apparatus of S. cerevisiae are involved in processing N-glycans (20), three of which are vital for the modification of the core Man8 structure that is exported from the ER (Fig. (Fig.1).1). In the cis-Golgi, Och1p initiates the first mannose residue necessary for the extended α1,6-linked mannose branch, a key component of polymannose-type glycans (30). Deletion of the Och1 gene alone leads to the lack of the outer chain, resulting in a majority of Man9 and Man10 structures, which represent core Man8 capped at the D1 and/or D3 arm with α1,3-linked mannose residues (40). In the trans-Golgi, Mnn1p is the sole α1,3-mannosytransferase responsible for adding these α1,3-mannose caps to the core glycans (11, 39, 58), while Mnn4p is a positive regulator involved in adding phosphomannose residues to both the core and outer chain (43, 44). FIG. 1. N-linked glycosylation pathway in wild-type and Δoch1 Δmnn1 Δmnn4 S. cerevisiae. In the ER, after en bloc transfer of Glc3Man9GlcNAc2 to nascent polyproteins, the three glucose residues are cleaved. In wild-type yeast, N-linked ... In this study, we sought to mimic the 2G12 epitope on the HIV-1 Env protein by producing a yeast strain that would express exclusively unprocessed, high-mannose glycans. We achieved this by generating a triple mutant of S. cerevisiae, a Δoch1 Δmnn1 Δmnn4 mutant (that we named TM [for triple mutant]) that produced almost homogenous Man8 glycans. The MAb 2G12 bound efficiently to the TM mutant, but not to the wild-type S. cerevisiae (that we named WT [for wild type]). At least four heavily glycosylated S. cerevisiae proteins supported 2G12 binding, with each of these possessing numerous N-linked glycosylation sites at a high density. Importantly, immune sera raised with whole cells of this mutant yeast, but not WT, cross-reacted in a carbohydrate-dependent manner with a broad array of mammalian cell-expressed Env glycoproteins from HIV-1 and simian immunodeficiency virus (SIV) strains, suggesting that genetically modified yeast proteins may serve as molecular scaffolds that recapitulate carbohydrate-dependent epitopes on the surface of the HIV-1 Env protein.
- Published
- 2008
16. Focused Dampening of Antibody Response to the Immunodominant Variable Loops by Engineered Soluble gp140
- Author
-
Ping Zhu, Dennis R. Burton, Fang-Hua Lee, Richard T. Wyatt, Bridget A. Puffer, Suganya Selvarajah, Robert W. Doms, Yuxing Li, and Kenneth H. Roux
- Subjects
Glycosylation ,Immunogen ,medicine.drug_class ,Blotting, Western ,Immunology ,Enzyme-Linked Immunosorbent Assay ,HIV Infections ,Context (language use) ,Immunodominance ,HIV Antibodies ,Biology ,Monoclonal antibody ,Epitope ,Cell Line ,Microscopy, Electron, Transmission ,Antigen ,Neutralization Tests ,Virology ,medicine ,Animals ,Humans ,Binding site ,env Gene Products, Human Immunodeficiency Virus ,HIV ,Infectious Diseases ,Biochemistry ,biology.protein ,Epitopes, B-Lymphocyte ,Rabbits ,Antibody - Abstract
Immunization studies with modified gp120 monomers using a hyperglycosylation strategy, in which undesired epitopes are masked by the selective incorporation of N-linked glycans, were described in a previous paper (Selvarajah S, et al., J Virol 2000;79:12148-12163). In this report, we applied the hyperglycosylation strategy to soluble uncleaved gp140 trimers to improve the antigenic and immunogenic profile in the context of a trimeric conformation of the immunogen. The JR-FL gp140 gene was added upstream of a soluble trimerization domain of chicken cartilage matrix (CART) protein and expressed predominantly as a trimer and called gp140-CART wild-type. In the hyperglycosylated gp140-CART mCHO(V) mutant, four extra sugar attachment motifs on the variable loops helped mask epitope recognition by monoclonal antibodies specific to the variable loops. The gp140-CART mCHO(V) mutant and gp140-CART wild-type soluble trimer protein were used to immunize rabbits. The gp140-CART mCHO(V) immune sera had reduced antibody response to the variable loops compared to gp140-CART wild-type immune sera as shown by peptide reactivity, competition assays, and the reduced ability of sera to neutralize SF162 virus (a variable loop neutralization-sensitive virus). The antibody response to the CD4 binding site was retained in the gp140-CART mCHO(V) mutant immune sera similar to gp140-CART wild-type immune sera. The results demonstrate that the strategy of hyperglycosylation is clearly useful in the context of a compact form of Env immunogen such as the soluble gp140 trimer in dampening responses to variable loops while maintaining responses to an important epitope, the CD4 binding site. However, the results also show that in order to elicit broadly neutralizing antibodies that target conserved epitopes, the soluble gp140 trimer immunogen template will require further modifications.
- Published
- 2008
17. Modulation of HIV and SIV neutralization sensitivity by DC-SIGN and mannose-binding lectin
- Author
-
Andrea Marzi, Ronald C. Desrosiers, Chawaree Chaipan, Mary Carrington, Stefan Pöhlmann, Robert W. Doms, Daniel A. Mitchell, and Tanja Fisch
- Subjects
Glycan ,Glycosylation ,viruses ,Simian Acquired Immunodeficiency Syndrome ,Attachment ,HIV Infections ,Receptors, Cell Surface ,MBL ,HIV Antibodies ,Antibodies, Viral ,medicine.disease_cause ,DC-SIGN ,Mannose-Binding Lectin ,Neutralization ,Cell Line ,03 medical and health sciences ,Neutralization Tests ,Polysaccharides ,Virology ,medicine ,Animals ,Humans ,Lectins, C-Type ,Antibody ,030304 developmental biology ,Mannan-binding lectin ,chemistry.chemical_classification ,0303 health sciences ,biology ,030306 microbiology ,HIV ,virus diseases ,Lectin ,Simian immunodeficiency virus ,3. Good health ,SIV ,chemistry ,biology.protein ,Simian Immunodeficiency Virus ,Glycoprotein ,Cell Adhesion Molecules - Abstract
The C-type lectin DC-SIGN binds to oligosaccharides on the human and simian immunodeficiency virus (HIV, SIV) envelope glycoproteins and promotes infection of susceptible cells. Here, we show that DC-SIGN recognizes glycans involved in SIV sensitivity to neutralizing antibodies and that binding to DC-SIGN confers neutralization resistance to an otherwise sensitive SIV variant. Moreover, we provide evidence that mannose-binding lectin (MBL) can interfere with HIV-1 neutralization by the carbohydrate-specific antibody 2G12.
- Published
- 2007
18. A simian immunodeficiency virus V3 loop mutant that does not efficiently use CCR5 or common alternative coreceptors is moderately attenuated in vivo
- Author
-
T Schneider, Frédéric Baribaud, Bridget A. Puffer, Zhiwei Chen, Jan Münch, Claas Otto, Thomas Gramberg, Heike Hofmann, Kerstin Mätz-Rensing, Christiane Stahl-Hennig, Jonathan L. Heeney, George J. Leslie, Peter ten Haaft, Frank Kirchhoff, Jacqueline D. Reeves, Andrea Marzi, Sheriff Aziz, Stefan Pöhlmann, Nicole Stolte, and Robert W. Doms
- Subjects
Receptors, CCR5 ,Chemokine receptor CCR5 ,viruses ,Simian Acquired Immunodeficiency Syndrome ,Pathogenesis ,V3 loop ,Virus Replication ,medicine.disease_cause ,Cell Line ,03 medical and health sciences ,Chemokine receptor ,Receptors, HIV ,0302 clinical medicine ,Viral entry ,Virology ,medicine ,Animals ,Viremia ,Tropism ,TAK-779 ,030304 developmental biology ,0303 health sciences ,Mucous Membrane ,biology ,Gene Products, env ,virus diseases ,Viral Load ,Virus Internalization ,Simian immunodeficiency virus ,Macaca mulatta ,CD4 Lymphocyte Count ,3. Good health ,Intestines ,Disease Models, Animal ,SIV ,Viral replication ,Simian AIDS ,030220 oncology & carcinogenesis ,Mutation ,Leukocytes, Mononuclear ,biology.protein ,RNA, Viral ,Simian Immunodeficiency Virus ,CCR5 ,Coreceptor - Abstract
Sexually transmitted HIV-1 strains utilize the chemokine receptor CCR5 for viral entry and inhibitors targeting this coreceptor offer great promise for antiretroviral therapy. They also raise the question, however, whether viral variants exhibiting altered coreceptor interactions and resistance against these antiviral agents might still be pathogenic. In the present study, we analyzed a SIVmac239 envelope (Env) mutant (239DL) containing two mutations in the V3 loop which reduced viral entry via CCR5 by 10- to 20-fold, disrupted utilization of common alternative SIV coreceptors and changed the way Env engaged CCR5. To evaluate its replicative capacity and pathogenic potential in vivo we infected six rhesus macaques with 239DL. We found that 239DL replication was only slightly attenuated early during infection. Thereafter, a D324V change, which restored efficient CCR5 usage and coincided with 239wt-like levels of viral replication, emerged in two animals. In contrast, the viral geno- and phenotype remained stable in the other four rhesus macaques. Although these animals had about 100-fold reduced viral RNA loads relative to 239wt-infected macaques, they showed pronounced CD4 T-cell depletion in the intestinal lamina propria, and one developed opportunistic infections and died with simian AIDS. Thus, changes in the V3 loop that diminished CCR5 usage and altered Env interactions with CCR5 reduced the pathogenic potential of SIVmac in rhesus macaques but did not abolish it entirely.
- Published
- 2007
19. A Haploid Genetic Screen Identifies Heparan Sulfate Proteoglycans Supporting Rift Valley Fever Virus Infection
- Author
-
Louis A. Altamura, Lucas T. Jae, Robert W. Doms, Amber M. Riblett, Vincent A. Blomen, Jason A. Wojcechowskyj, and Thijn R. Brummelkamp
- Subjects
0301 basic medicine ,Immunology ,Virus Attachment ,Microbiology ,Virus ,Cell Line ,03 medical and health sciences ,chemistry.chemical_compound ,Virology ,medicine ,Humans ,Genetic Testing ,Rift Valley fever ,Pathogen ,030102 biochemistry & molecular biology ,biology ,Heparan sulfate ,medicine.disease ,biology.organism_classification ,Rift Valley fever virus ,3. Good health ,Virus-Cell Interactions ,030104 developmental biology ,chemistry ,Interaction with host ,Mutagenesis ,Insect Science ,Bunyaviridae ,Encephalitis ,Heparan Sulfate Proteoglycans ,Genetic screen - Abstract
Rift Valley fever virus (RVFV) causes recurrent insect-borne epizootics throughout the African continent, and infection of humans can lead to a lethal hemorrhagic fever syndrome. Deep mutagenesis of haploid human cells was used to identify host factors required for RVFV infection. This screen identified a suite of enzymes involved in glycosaminoglycan (GAG) biogenesis and transport, including several components of the cis -oligomeric Golgi (COG) complex, one of the central components of Golgi complex trafficking. In addition, disruption of PTAR1 led to RVFV resistance as well as reduced heparan sulfate surface levels, consistent with recent observations that PTAR1-deficient cells exhibit altered Golgi complex morphology and glycosylation defects. A variety of biochemical and genetic approaches were utilized to show that both pathogenic and attenuated RVFV strains require GAGs for efficient infection on some, but not all, cell types, with the block to infection being at the level of virion attachment. Examination of other members of the Bunyaviridae family for GAG-dependent infection suggested that the interaction with GAGs is not universal among bunyaviruses, indicating that these viruses, as well as RVFV on certain cell types, employ additional unidentified virion attachment factors and/or receptors. IMPORTANCE Rift Valley fever virus (RVFV) is an emerging pathogen that can cause severe disease in humans and animals. Epizootics among livestock populations lead to high mortality rates and can be economically devastating. Human epidemics of Rift Valley fever, often initiated by contact with infected animals, are characterized by a febrile disease that sometimes leads to encephalitis or hemorrhagic fever. The global burden of the pathogen is increasing because it has recently disseminated beyond Africa, which is of particular concern because the virus can be transmitted by widely distributed mosquito species. There are no FDA-licensed vaccines or antiviral agents with activity against RVFV, and details of its life cycle and interaction with host cells are not well characterized. We used the power of genetic screening in human cells and found that RVFV utilizes glycosaminoglycans to attach to host cells. This furthers our understanding of the virus and informs the development of antiviral therapeutics.
- Published
- 2015
20. Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans
- Author
-
Fang-Hua Lee, Yu Geng, Hong Zhang, Hu Fu, Robert W. Doms, Robert J. Luallen, and Bingfen Liu
- Subjects
Glycan ,Antigenicity ,Mannose ,Antibodies, Heterophile ,Saccharomyces cerevisiae ,Epitope ,Article ,chemistry.chemical_compound ,Neutralization Tests ,Polysaccharides ,Animals ,Humans ,Neutralizing antibody ,Antibodies, Fungal ,chemistry.chemical_classification ,General Veterinary ,General Immunology and Microbiology ,biology ,Immunogenicity ,Public Health, Environmental and Occupational Health ,virus diseases ,Virology ,Antibodies, Neutralizing ,Infectious Diseases ,chemistry ,biology.protein ,HIV-1 ,Molecular Medicine ,Rabbits ,Antibody ,Glycoprotein - Abstract
The glycan shield on the human immunodeficiency virus 1 (HIV-1) envelope (Env) glycoprotein has drawn attention as a target for HIV-1 vaccine design given that an increasing number of potent and broadly neutralizing antibodies (bNAbs) recognize epitopes entirely or partially comprised of high mannose type N-linked glycans. In an attempt to generate immunogens that target the glycan shield of HIV-1, we previously engineered a triple mutant (TM) strain of Saccharomyces cerevisiae that results in exclusive presentation of high mannose type N-glycans, and identified five TM yeast glycoproteins that support strong binding of 2G12, a bNAb that targets a cluster of high mannose glycans on the gp120 subunit of Env. Here, we further analyzed the antigenicity and immunogenicity of these proteins in inducing anti-HIV responses. Our study demonstrated that the 2G12-reactive TM yeast glycoproteins efficiently bound to recently identified bNAbs including PGT125-130 and PGT135 that recognize high mannose glycan-dependent epitopes. Immunization of rabbits with a single TM yeast glycoprotein (Gp38 or Pst1), when conjugated to a promiscuous T-cell epitope peptide and coadministered with a Toll-like receptor 2 agonist, induced glycan-specific HIV-1 Env cross-reactive antibodies. The immune sera bound to both synthetic mannose oligosaccharides and gp120 proteins from a broad range of HIV-1 strains. The purified antibodies recognized and captured virions that contain both complex- and high mannose-type of N-glycans, and potently neutralized virions from different HIV-1 clades but only when the virions were enforced to retain high mannose N-glycans. This study provides insights into the elicitation of anti-carbohydrate, HIV-1 Env-cross reactive antibodies with a heterologous glycoprotein and may have applications in the design and administration of immunogens that target the viral glycan shield for development of an effective HIV-1 vaccine.
- Published
- 2015
21. Development and characterization of a Rift Valley fever virus cell–cell fusion assay using alphavirus replicon vectors
- Author
-
Andrea Bertolotti-Ciarlet, Claire Marie Filone, Mark T. Heise, and Robert W. Doms
- Subjects
Phlebovirus ,Rift Valley Fever ,Bunyaviridae ,Genetic Vectors ,Entry ,Alphavirus ,Membrane Fusion ,Article ,Virus ,Cell Line ,Alphavirus vector ,Viral Proteins ,Cricetinae ,Virology ,Chlorocebus aethiops ,Animals ,Humans ,Fusion ,Vero Cells ,Glycoproteins ,Host cell surface ,Cell fusion ,biology ,Lipid bilayer fusion ,Rift Valley fever virus ,biology.organism_classification ,Replicon ,Membrane Fusion Activity - Abstract
Rift Valley fever virus (RVFV), a member of the Phlebovirus genus in the Bunyaviridae family, is transmitted by mosquitoes and infects both humans and domestic animals, particularly cattle and sheep. Since primary RVFV strains must be handled in BSL-3+ or BSL-4 facilities, a RVFV cell–cell fusion assay will facilitate the investigation of RVFV glycoprotein function under BSL-2 conditions. As for other members of the Bunyaviridae family, RVFV glycoproteins are targeted to the Golgi, where the virus buds, and are not efficiently delivered to the cell surface. However, overexpression of RVFV glycoproteins using an alphavirus replicon vector resulted in the expression of the glycoproteins on the surface of multiple cell types. Brief treatment of RVFV glycoprotein expressing cells with mildly acidic media (pH 6.2 and below) resulted in rapid and efficient syncytia formation, which we quantified by β-galactosidase α-complementation. Fusion was observed with several cell types, suggesting that the receptor(s) for RVFV is widely expressed or that this acid-dependent virus does not require a specific receptor to mediate cell–cell fusion. Fusion occurred over a broad temperature range, as expected for a virus with both mosquito and mammalian hosts. In contrast to cell fusion mediated by the VSV-G glycoprotein, RVFV glycoprotein-dependent cell fusion could be prevented by treating target cells with trypsin, indicating that one or more proteins (or protein-associated carbohydrate) on the host cell surface are needed to support membrane fusion. The cell–cell fusion assay reported here will make it possible to study the membrane fusion activity of RVFV glycoproteins in a high-throughput format and to screen small molecule inhibitors for the ability to block virus-specific membrane fusion.
- Published
- 2006
22. Functional impact of HIV coreceptor-binding site mutations
- Author
-
John M. Muchiri, Sarah S.W. Baik, John L. Miamidian, Robert W. Doms, Mark J. Biscone, Fang-Hua Lee, and Jacqueline D. Reeves
- Subjects
Env ,Enfuvirtide ,AMD-3100 ,viruses ,Coreceptor-binding site ,Context (language use) ,CCR5 receptor antagonist ,Plasma protein binding ,HIV Envelope Protein gp120 ,Biology ,Membrane Fusion ,Virus ,Cell Line ,03 medical and health sciences ,Receptors, HIV ,HIV Fusion Inhibitors ,Virology ,medicine ,Humans ,Binding site ,Fusion ,030304 developmental biology ,TAK-779 ,Genetics ,0303 health sciences ,Binding Sites ,030302 biochemistry & molecular biology ,Lipid bilayer fusion ,virus diseases ,HIV ,Entry inhibitor ,HIV Envelope Protein gp41 ,Peptide Fragments ,3. Good health ,Mutation ,HIV-1 ,Coreceptor ,Protein Binding ,medicine.drug - Abstract
The bridging sheet region of the gp120 subunit of the HIV-1 Env protein interacts with the major virus coreceptors, CCR5 and CXCR4. We examined the impact of mutations in and adjacent to the bridging sheet region of an X4 tropic HIV-1 on membrane fusion and entry inhibitor susceptibility. When the V3-loop of this Env was changed so that CCR5 was used, the effects of these same mutations on CCR5 use were assayed as well. We found that coreceptor-binding site mutations had greater effects on CXCR4-mediated fusion and infection than when CCR5 was used as a coreceptor, perhaps related to differences in coreceptor affinity. The mutations also reduced use of the alternative coreceptors CCR3 and CCR8 to varying degrees, indicating that the bridging sheet region is important for the efficient utilization of both major and minor HIV coreceptors. As seen before with a primary R5 virus strain, bridging sheet mutations increased susceptibility to the CCR5 inhibitor TAK-779, which correlated with CCR5 binding efficiency. Bridging sheet mutations also conferred increased susceptibility to the CXCR4 ligand AMD-3100 in the context of the X4 tropic Env. However, these mutations had little effect on the rate of membrane fusion and little effect on susceptibility to enfuvirtide, a membrane fusion inhibitor whose activity is dependent in part on the rate of Env-mediated membrane fusion. Thus, mutations that reduce coreceptor binding and enhance susceptibility to coreceptor inhibitors can affect fusion and enfuvirtide susceptibility in an Env context-dependent manner.
- Published
- 2006
- Full Text
- View/download PDF
23. Comparing Antigenicity and Immunogenicity of Engineered gp120
- Author
-
Dennis R. Burton, Bridget A. Puffer, Mansun Law, Robert W. Doms, Ralph Pantophlet, and Suganya Selvarajah
- Subjects
Models, Molecular ,Antigenicity ,Glycosylation ,viruses ,Immunology ,Enzyme-Linked Immunosorbent Assay ,HIV Antibodies ,HIV Envelope Protein gp120 ,Biology ,Protein Engineering ,Microbiology ,Virus ,Epitope ,Epitopes ,chemistry.chemical_compound ,Immune system ,Neutralization Tests ,Virology ,Vaccines and Antiviral Agents ,Animals ,Humans ,Biotinylation ,Immunogenicity ,Amino Acid Substitution ,chemistry ,Immunization ,Insect Science ,HIV-1 ,biology.protein ,Rabbits ,Antibody - Abstract
We have engineered monomeric gp120 in such a way as to favorably present the conserved epitope for the broadly neutralizing antibody b12 while lowering the exposure of epitopes recognized by some weakly neutralizing and nonneutralizing antibodies. The work presented here describes the immune response in rabbits immunized with two prototype, engineered gp120s to explore the relationship between antigenicity and immunogenicity for these mutants. The GDMR gp120 mutant (residues 473 to 476 on gp120 altered from GDMR to AAAA) has a series of substitutions on the edge of the CD4 binding site (CD4bs), and the mCHO gp120 mutant has seven extra glycans relative to the wild-type protein. Importantly, serum mapping showed that both mutants did not elicit antibodies against a number of epitopes that had been targeted for dampening. The sera from rabbits immunized with the GDMR gp120 mutant neutralized some primary viruses at levels somewhat better than the wild-type gp120 immune sera as a result of an increased elicitation of anti-V3 antibodies. Unlike wild-type gp120 immune sera, GDMR gp120 immune sera failed to neutralize HXBc2, a T-cell line adapted (TCLA) virus. This was associated with loss of CD4bs/CD4-induced antibodies that neutralize TCLA but not primary viruses. The mCHO gp120 immune sera did not neutralize primary viruses to any significant degree, reflecting the masking of epitopes of even weakly neutralizing antibodies without eliciting b12-like antibodies. These results show that antibody responses to multiple epitopes on gp120 can be dampened. More precise focusing to a neutralizing epitope will likely require several iterations comparing antigenicity and immunogenicity of engineered proteins.
- Published
- 2005
24. Castanospermine, a Potent Inhibitor of Dengue Virus Infection In Vitro and In Vivo
- Author
-
Michael S. Diamond, Theodore C. Pierson, Kelly Lane, Michael Engle, Robert W. Doms, Yi Zhou, Brian J. Geiss, and Kevin Whitby
- Subjects
viruses ,Immunology ,Dengue virus ,Biology ,medicine.disease_cause ,Antiviral Agents ,Microbiology ,Virus ,Dengue fever ,Dengue ,Mice ,chemistry.chemical_compound ,Virology ,Vaccines and Antiviral Agents ,medicine ,Animals ,Antibody-dependent enhancement ,Infectivity ,Yellow fever ,Indolizines ,Virion ,Dengue Virus ,medicine.disease ,Mice, Inbred C57BL ,Castanospermine ,chemistry ,Insect Science ,RNA, Viral ,Viral disease ,Yellow fever virus ,West Nile virus ,West Nile Fever - Abstract
Previous studies have suggested that α-glucosidase inhibitors such as castanospermine and deoxynojirimycin inhibit dengue virus type 1 infection by disrupting the folding of the structural proteins prM and E, a step crucial to viral secretion. We extend these studies by evaluating the inhibitory activity of castanospermine against a panel of clinically important flaviviruses including all four serotypes of dengue virus, yellow fever virus, and West Nile virus. Using in vitro assays we demonstrated that infections by all serotypes of dengue virus were inhibited by castanospermine. In contrast, yellow fever virus and West Nile virus were partially and almost completely resistant to the effects of the drug, respectively. Castanospermine inhibited dengue virus infection at the level of secretion and infectivity of viral particles. Importantly, castanospermine prevented mortality in a mouse model of dengue virus infection, with doses of 10, 50, and 250 mg/kg of body weight per day being highly effective at promoting survival (P≤ 0.0001). Correspondingly, castanospermine had no adverse or protective effect on West Nile virus mortality in an analogous mouse model. Overall, our data suggest that castanospermine has a strong antiviral effect on dengue virus infection and warrants further development as a possible treatment in humans.
- Published
- 2005
25. Cellular Localization and Antigenic Characterization of Crimean-Congo Hemorrhagic Fever Virus Glycoproteins
- Author
-
Jonathan Smith, Jeanne M. McFalls, Adolfo García-Sastre, Louis A. Altamura, Robert W. Doms, Andrea Bertolotti-Ciarlet, Connie S. Schmaljohn, Karin Strecker, Natalia Frias-Staheli, and Jason Paragas
- Subjects
Immunology ,Golgi Apparatus ,Biology ,Antibodies, Viral ,Microbiology ,Virus ,Cell Line ,Mice ,Viral Proteins ,symbols.namesake ,Neutralization Tests ,Virology ,Animals ,Humans ,Antigens, Viral ,Cellular localization ,Glycoproteins ,chemistry.chemical_classification ,Mice, Inbred BALB C ,Immunization, Passive ,Antibodies, Monoclonal ,Golgi Targeting ,Golgi apparatus ,biology.organism_classification ,Molecular biology ,Virus-Cell Interactions ,Disease Models, Animal ,Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase ,Solubility ,chemistry ,Ectodomain ,Cytoplasm ,Insect Science ,Hemorrhagic Fever Virus, Crimean-Congo ,symbols ,Hemorrhagic Fever, Crimean ,Bunyaviridae ,Glycoprotein - Abstract
Crimean-Congo hemorrhagic fever virus (CCHFV), a member of the genus Nairovirus of the family Bunyaviridae , causes severe disease with high rates of mortality in humans. The CCHFV M RNA segment encodes the virus glycoproteins G N and G C . To understand the processing and intracellular localization of the CCHFV glycoproteins as well as their neutralization and protection determinants, we produced and characterized monoclonal antibodies (MAbs) specific for both G N and G C . Using these MAbs, we found that G N predominantly colocalized with a Golgi marker when expressed alone or with G C , while G C was transported to the Golgi apparatus only in the presence of G N . Both proteins remained endo-β- N -acetylglucosaminidase H sensitive, indicating that the CCHFV glycoproteins are most likely targeted to the cis Golgi apparatus. Golgi targeting information partly resides within the G N ectodomain, because a soluble version of G N lacking its transmembrane and cytoplasmic domains also localized to the Golgi apparatus. Coexpression of soluble versions of G N and G C also resulted in localization of soluble G C to the Golgi apparatus, indicating that the ectodomains of these proteins are sufficient for the interactions needed for Golgi targeting. Finally, the mucin-like and P35 domains, located at the N terminus of the G N precursor protein and removed posttranslationally by endoproteolysis, were required for Golgi targeting of G N when it was expressed alone but were dispensable when G C was coexpressed. In neutralization assays on SW-13 cells, MAbs to G C , but not to G N , prevented CCHFV infection. However, only a subset of G C MAbs protected mice in passive-immunization experiments, while some nonneutralizing G N MAbs efficiently protected animals from a lethal CCHFV challenge. Thus, neutralization of CCHFV likely depends not only on the properties of the antibody, but on host cell factors as well. In addition, nonneutralizing antibody-dependent mechanisms, such as antibody-dependent cell-mediated cytotoxicity, may be involved in the in vivo protection seen with the MAbs to G C .
- Published
- 2005
26. An infectious West Nile Virus that expresses a GFP reporter gene
- Author
-
Carl W. Davis, Laura E. Valentine, Sheri L. Hanna, Theodore C. Pierson, Bridget A. Puffer, Melanie A. Samuel, Asim A. Ahmed, Michael S. Diamond, and Robert W. Doms
- Subjects
viruses ,Green Fluorescent Proteins ,Gene Expression ,Biology ,Antibodies, Viral ,Transfection ,Virus Replication ,Recombinant virus ,Virus ,Cell Line ,Green fluorescent protein ,Plasmid ,Genes, Reporter ,Molecular clone ,Cricetinae ,Virology ,Animals ,Humans ,West Nile Virus ,Reporter gene ,Flavivirus ,Antibodies, Monoclonal ,virus diseases ,biology.organism_classification ,Recombinant Proteins ,Kinetics ,Viral replication ,Interferon Type I ,HeLa Cells ,Plasmids - Abstract
West Nile virus is a mosquito-borne, neurotropic flavivirus that causes encephalitis in humans and animals. Since being introduced into the Western hemisphere in 1999, WNV has spread rapidly across North America, identifying this virus as an important emerging pathogen. In this study, we developed a DNA-launched infectious molecular clone of WNV that encodes a GFP reporter gene. Transfection of cells with the plasmid encoding this recombinant virus (pWNII-GFP) resulted in the production of infectious WNV capable of expressing GFP at high levels shortly after infection of a variety of cell types, including primary neurons and dendritic cells. Infection of cells with WNII-GFP virus was productive, and could be inhibited with both monoclonal antibodies and interferon-β, highlighting the potential of this system in the development and characterization of novel inhibitors and therapeutics for WNV infection. As expected, insertion of the reporter gene into the viral genome was associated with a reduced rate of viral replication, providing the selective pressure for the development of variants that no longer encoded the full-length reporter gene cassette. We anticipate this DNA-based, infectious WNV reporter virus will allow novel approaches for the study of WNV infection and its inhibition both in vitro and in vivo.
- Published
- 2005
27. Determinants within gp120 and gp41 contribute to CD4 independence of SIV Envs
- Author
-
Robert W. Doms, Bridget A. Puffer, Theodore C. Pierson, and Louis A. Altamura
- Subjects
Env ,Chemokine receptor CCR5 ,viruses ,Retroviridae Proteins ,medicine.disease_cause ,Gp41 ,Neutralization ,Virus ,Cell Line ,Cell Fusion ,Chemokine receptor ,Viral envelope ,Viral Envelope Proteins ,Neutralization Tests ,Virology ,medicine ,Animals ,Humans ,Binding site ,Membrane Glycoproteins ,biology ,virus diseases ,Simian immunodeficiency virus ,Macaca mulatta ,Amino Acid Substitution ,CD4 Antigens ,biology.protein ,Simian Immunodeficiency Virus - Abstract
Entry of simian immunodeficiency virus (SIV) into cells is mediated by binding of the viral envelope (Env) glycoprotein to cellular CD4 and chemokine receptor molecules. Interaction of the Env gp120 subunit with CD4 induces conformational changes that result in exposure of a conserved coreceptor binding site. The chemokine receptor CCR5 is the major coreceptor used for SIV entry. Many SIV Envs have the ability to bind directly to CCR5 in the absence of CD4, and CD4-independent SIVs have been shown to exhibit macrophage tropism, enhanced neutralization sensitivity, and reduced pathogenicity in nonhuman primates. SIVmac239 is a pathogenic, T-tropic, neutralization-resistant virus which encodes a CD4-dependent Env. By contrast, the SIVmac316 virus, which differs from 239 in Env by only eight amino acid substitutions and a gp41 cytoplasmic domain truncation, exhibits macrophage tropism in vitro, attenuated pathogenesis, neutralization sensitivity, and CD4-independent entry. We mapped the residues contributing to CD4-independent entry to substitutions at position 165 in the V1/V2 region of gp120 and position 573 of gp41. We find that substitution of both residues in replication-competent SIVmac239 virus results in gain of CD4 independence and enhanced neutralization sensitivity. By contrast, the converse substitutions placed in the background of SIVmac316 resulted in loss of CD4 independence and decreased neutralization sensitivity. Thus, as few as two amino acid changes can have dramatic effects on SIV Env phenotype.
- Published
- 2004
- Full Text
- View/download PDF
28. Impact of Mutations in the Coreceptor Binding Site on Human Immunodeficiency Virus Type 1 Fusion, Infection, and Entry Inhibitor Sensitivity
- Author
-
Mark J. Biscone, John L. Miamidian, Theodore C. Pierson, Fang-Hua Lee, Robert W. Doms, Jacqueline D. Reeves, and Navid Ahmad
- Subjects
Enfuvirtide ,Receptors, CCR5 ,Anti-HIV Agents ,viruses ,Immunology ,Replication ,CCR5 receptor antagonist ,HIV Envelope Protein gp120 ,Biology ,Membrane Fusion ,Microbiology ,Virus ,Cell Line ,Structure-Activity Relationship ,Virology ,medicine ,Humans ,Binding site ,Infectivity ,Binding Sites ,virus diseases ,Lipid bilayer fusion ,Amides ,HIV Envelope Protein gp41 ,Peptide Fragments ,Entry inhibitor ,Quaternary Ammonium Compounds ,Insect Science ,CD4 Antigens ,Mutation ,HIV-1 ,biology.protein ,Antibody ,medicine.drug - Abstract
An increasingly large number of antiviral agents that prevent entry of human immunodeficiency virus (HIV) into cells are in preclinical and clinical development. The envelope (Env) protein of HIV is the major viral determinant that affects sensitivity to these compounds. To understand how changes in Env can impact entry inhibitor sensitivity, we introduced six mutations into the conserved coreceptor binding site of the R5 HIV-1 strain YU-2 and measured the effect of these changes on CD4 and coreceptor binding, membrane fusion levels and rates, virus infection, and sensitivity to the fusion inhibitors enfuvirtide (T-20) and T-1249, the CCR5 inhibitor TAK-779, and an antibody to CD4. The mutations had little effect on CD4 binding but reduced CCR5 binding to various extents. In general, reductions in coreceptor binding efficiency resulted in slower fusion kinetics and increased sensitivity to TAK-779 and enfuvirtide. In addition, low CCR5 binding usually reduced overall fusion and infection levels. However, one mutation adjacent to the bridging sheet β21 strand, P438A, had little effect on fusion activity, fusion rate, infectivity, or sensitivity to enfuvirtide or T-1249 despite causing a marked reduction in CCR5 binding and a significant increase in TAK-779 sensitivity. Thus, our findings indicate that changes in the coreceptor binding site of Env can modulate its fusion activity, infectivity, and entry inhibitor sensitivity by multiple mechanisms and suggest that reductions in coreceptor binding do not always result in prolonged fusion kinetics and increased sensitivity to enfuvirtide.
- Published
- 2004
29. HIV Transmission
- Author
-
Carl W. Davis and Robert W. Doms
- Subjects
Male ,CD4-Positive T-Lymphocytes ,Receptors, CXCR4 ,Sexual transmission ,Anti-HIV Agents ,Sexual Behavior ,Immunology ,Human immunodeficiency virus (HIV) ,HIV Infections ,Cervix Uteri ,In Vitro Techniques ,Biology ,medicine.disease_cause ,Article ,Virus ,Receptors, HIV ,Neutralization Tests ,Microbicide ,medicine ,Humans ,Immunology and Allergy ,Hiv transmission ,mucosa ,transmission ,Dendritic Cells ,Virology ,AIDS ,Microbicides for sexually transmitted diseases ,Cervical tissue ,CCR5 Receptor Antagonists ,CD4 Antigens ,Commentary ,HIV-1 ,Female ,microbicide ,Ex vivo - Abstract
Identification of cellular factors involved in HIV-1 entry and transmission at mucosal surfaces is critical for understanding viral pathogenesis and development of effective prevention strategies. Here we describe the evaluation of HIV-1 entry inhibitors for their ability to prevent infection of, and dissemination from, human cervical tissue ex vivo. Blockade of CD4 alone or CCR5 and CXCR4 together inhibited localized mucosal infection. However, simultaneous blockade of CD4 and mannose-binding C-type lectin receptors including dendritic cell-specific intercellular adhesion molecule-grabbing integrin was required to inhibit HIV-1 uptake and dissemination by migratory cells. In contrast, direct targeting of HIV-1 by neutralizing mAb b12 and CD4-IgG2 (PRO-542) blocked both localized infection and viral dissemination pathways. Flow cytometric analysis and immunostaining of migratory cells revealed two major populations, CD3(+)HLA-DR(-) and CD3(-)HLA-DR(+) cells, with a significant proportion of the latter also expressing dendritic cell-specific intercellular adhesion molecule-grabbing integrin. Bead depletion studies demonstrated that such HLA-DR(+) cells accounted for as much as 90% of HIV-1 dissemination. Additional studies using immature monocyte-derived dendritic cells demonstrated that although mannose-binding C-type lectin receptors and CD4 are the principal receptors for gp120, other mechanisms may account for virus capture. Our identification of the predominant receptors involved in HIV-1 infection and dissemination within human cervical tissue highlight important targets for microbicide development.
- Published
- 2004
30. Amino Acid 324 in the Simian Immunodeficiency Virus SIVmac V3 Loop Can Confer CD4 Independence and Modulate the Interaction with CCR5 and Alternative Coreceptors
- Author
-
Steffen Lorenz, Claas Otto, George J. Leslie, Silke Meister, Frank Kirchhoff, Bridget A. Puffer, Mandy Krumbiegel, Armin Papkalla, Jacqueline D. Reeves, Jan Münch, Stefan Pöhlmann, Robert W. Doms, Carl W. Davis, and Andrea Marzi
- Subjects
Virus genetics ,Receptors, CCR5 ,Receptors, Peptide ,viruses ,Immunology ,V3 loop ,Biology ,medicine.disease_cause ,Microbiology ,Macaque ,Cell Line ,Receptors, G-Protein-Coupled ,Cell Fusion ,Viral Envelope Proteins ,Virology ,biology.animal ,medicine ,Animals ,Humans ,Tropism ,chemistry.chemical_classification ,Cell fusion ,virus diseases ,Simian immunodeficiency virus ,biology.organism_classification ,Macaca mulatta ,Virus-Cell Interactions ,Amino acid ,Amino Acid Substitution ,chemistry ,Organ Specificity ,Insect Science ,CD4 Antigens ,Lentivirus ,Receptors, Virus ,Simian Immunodeficiency Virus ,HeLa Cells ,Protein Binding - Abstract
The V3 loop of the simian immunodeficiency virus (SIV) envelope protein (Env) largely determines interactions with viral coreceptors. To define amino acids in V3 that are critical for coreceptor engagement, we functionally characterized Env variants with amino acid substitutions at position 324 in V3, which has previously been shown to impact SIV cell tropism. These changes modulated CCR5 engagement and, in some cases, allowed the efficient usage of CCR5 in the absence of CD4. The tested amino acid substitutions had highly differential effects on viral infectivity. Eleven of sixteen substitutions disrupted entry via CCR5 or the alternative coreceptor GPR15. Nevertheless, most of these variants replicated in the macaque T-cell line 221-89 and some also replicated in rhesus macaque peripheral blood monocytes, suggesting that efficient usage of CCR5 and GPR15 on cell lines is not a prerequisite for SIV replication in primary cells. Four variants showed enhanced entry into the macaque sMagi reporter cell line. However, sMagi cells did not express appreciable amounts of CCR5 and GPR15 mRNA, and entry into these cells was not efficiently blocked by a small-molecule CCR5 antagonist, suggesting that sMagi cells express as-yet-unidentified entry cofactors. In summary, we found that a single amino acid at position 324 in the SIV Env V3 loop can modulate both the efficiency and the types of coreceptors engaged by Env and allow for CD4-independent fusion in some cases.
- Published
- 2004
31. HIV vaccine design and the neutralizing antibody problem
- Author
-
Wayne C. Koff, Gary J. Nabel, Joseph Sodroski, Robert W. Doms, Ronald C. Desrosiers, Dennis R. Burton, John P. Moore, Richard T. Wyatt, Ian A. Wilson, and Peter D. Kwong
- Subjects
Models, Molecular ,Immunology ,Human immunodeficiency virus (HIV) ,HIV Antibodies ,HIV Envelope Protein gp120 ,medicine.disease_cause ,Epitopes ,Acquired immunodeficiency syndrome (AIDS) ,Neutralization Tests ,medicine ,Humans ,Immunology and Allergy ,HIV vaccine ,Neutralizing antibody ,AIDS Vaccines ,biology ,business.industry ,Antibodies, Monoclonal ,medicine.disease ,Virology ,HIV Envelope Protein gp41 ,Drug Design ,HIV-1 ,biology.protein ,Antibody ,business - Abstract
Eliciting broadly neutralizing antibodies to human immunodeficiency virus could bring closer the goal of a successful AIDS vaccine. Here the International AIDS Vaccine Initiative Neutralizing Antibody Consortium discusses current approaches to overcome the problems faced.
- Published
- 2004
32. Mutations in the C3 region of human and simian immunodeficiency virus envelope have differential effects on viral infectivity, replication, and CD4-dependency
- Author
-
Frank Kirchhoff, Claas Otto, Robert W. Doms, Bridget A. Puffer, and Stefan Pöhlmann
- Subjects
viruses ,Biology ,Virus Replication ,medicine.disease_cause ,Membrane Fusion ,CD4-dependency ,Virus ,Cell Line ,Structure-Activity Relationship ,Viral Envelope Proteins ,C3 region ,Envelope ,Viral entry ,Virology ,medicine ,Animals ,Humans ,Genetics ,Infectivity ,Mutation ,HIV ,virus diseases ,Lipid bilayer fusion ,Simian immunodeficiency virus ,Macaca mulatta ,Amino Acid Substitution ,Viral replication ,CD4 Antigens ,HIV-1 ,Tissue tropism ,Simian Immunodeficiency Virus ,SIVmac - Abstract
Residues within the highly conserved C3 region of human and simian immunodeficiency virus (HIV, SIV) envelope proteins (Envs) bind directly to the cellular CD4 receptor. However, substitutions of D385, which is critical for CD4 engagement along with other changes such as G382R, G383R, frequently arise in SIV mac-infected macaques. We investigated the influence of substitutions in the SIVmac and HIV-1 C3 regions on viral entry, dependence on CD4, and replication. Mutations flanking the C3 region such as G382R or V388A enhanced and changes within the C3 region (i.e., G383R or D385N) impaired SIVmac infectivity. Several naturally occurring sequence variations in the SIVmac Env C3 region facilitated CD4-independent membrane fusion but abrogated viral replication, suggesting that efficient infection requires additional changes elsewhere in Env. Substitutions of S365R and D368G in the HIV-1 Env, which correspond to G382 and D385 in SIVmac Env, consistently impaired viral infectivity. In contrast, mutation of D368N resulted in a virus that could not spread in cells expressing low levels of CD4, but which replicated efficiently when high levels of CD4 were expressed. Thus, changes in the C3 region of HIV-1 or SIVmac Env can have differential effects on viral infectivity and CD4-dependency. We conclude that substitutions flanking the C3 region in SIVmac Env such as G382R or V388A represent one step toward adaptation to growth in target cells expressing low CD4 levels, whereas changes within the C3 region that disrupt CD4 binding might indicate the emergence of CD4-independent variants at later stages of infection, which could potentially broaden viral tropism.
- Published
- 2003
- Full Text
- View/download PDF
33. The entry of entry inhibitors: A fusion of science and medicine
- Author
-
Robert W. Doms and John P. Moore
- Subjects
Chemokine ,Multidisciplinary ,Protease ,viruses ,medicine.medical_treatment ,Receptor expression ,HIV Infections ,Viral Load ,Biology ,Membrane Fusion ,Virology ,Reverse transcriptase ,Virus ,HIV Fusion Inhibitors ,Viral entry ,Perspective ,HIV-1 ,medicine ,biology.protein ,Humans ,Receptor ,Viral load ,Monitoring, Physiologic - Abstract
For HIV-1 to enter a cell, its envelope protein (Env) must sequentially engage CD4 and a chemokine coreceptor, triggering conformational changes in Env that ultimately lead to fusion between the viral and host cell membranes. Each step of the virus entry pathway is a potential target for novel antiviral agents termed entry inhibitors. A growing number of entry inhibitors are under clinical development, with one having already been licensed by the Food and Drug Administration. With the emergence of virus strains that are largely resistant to existing reverse transcriptase and protease inhibitors, the development of entry inhibitors comes at an opportune time. Nonetheless, because all entry inhibitors target in some manner the highly variable Env protein of HIV-1, there are likely to be challenges in their efficient application that are unique to this class of drugs. Env density, receptor expression levels, and differences in affinity and receptor presentation are all factors that could influence the clinical response to this promising class of new antiviral agents.
- Published
- 2003
34. Unique Pattern of Convergent Envelope Evolution in Simian Immunodeficiency Virus-Infected Rapid Progressor Macaques: Association with CD4-Independent Usage of CCR5
- Author
-
Bridget A. Puffer, Vanessa M. Hirsch, Robert W. Doms, and Houman Dehghani
- Subjects
Time Factors ,Receptors, CCR5 ,viruses ,Molecular Sequence Data ,Immunology ,Simian Acquired Immunodeficiency Syndrome ,V3 loop ,medicine.disease_cause ,Microbiology ,Macaque ,Virus ,Evolution, Molecular ,Immune system ,Viral Envelope Proteins ,Virology ,biology.animal ,medicine ,Animals ,Amino Acid Sequence ,biology ,Genetic Variation ,Sequence Analysis, DNA ,Simian immunodeficiency virus ,Macaca mulatta ,Amino Acid Substitution ,Viral replication ,Giant cell ,Insect Science ,Viral evolution ,CD4 Antigens ,Pathogenesis and Immunity ,Simian Immunodeficiency Virus ,Macaca nemestrina - Abstract
The rate of disease development in simian immunodeficiency virus (SIV) infection of macaques varies considerably among individual macaques. While the majority of macaques inoculated with pathogenic SIV develop AIDS within a period of 1 to 2 years, a minority exhibit a rapid disease course characterized by absence or transience of humoral and cellular immune responses and high levels of virus replication with widespread dissemination of SIV in macrophages and multinucleated giant cells. The goal of this study was to examine viral evolution in three SIVsmE543-3-inoculated rapid progressors to determine the contribution of viral evolution to the development of rapid disease and the effect of the absence of immune pressure upon viral evolution. PCR was used to amplify and clone the entire SIV genome from tissues collected at necropsy, and the course of viral evolution was assessed byenvsequences cloned from sequential plasma samples of one rapid progressor (RP) macaque. The majority of sequence changes in RP macaques occurred in the envelope gene. Substitutions were observed in all three animals at specific conserved residues in envelope, including loss of a glycosylation site in V1/V2, a D-to-N/V substitution in a highly conserved GDPE motif, and a P-to-V/H/T substitution in the V3 loop analog. A cell-cell fusion assay revealed that representativeenvclones utilized CCR5 as a coreceptor, independent of CD4. The selection of specific substitutions in envelope in RP macaques suggests novel selection pressures on virus in such animals and suggests that viral variants that evolve in these animals may play a role in disease progression.
- Published
- 2003
35. Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR
- Author
-
Zhiwei Chen, Jie Zhang, Angela Granelli-Piperno, George Lin, Stefan Pöhlmann, Frédéric Baribaud, Robert W. Doms, Charles M. Rice, Jane A. McKeating, and George J. Leslie
- Subjects
Immunology ,Receptors, Cell Surface ,Hepacivirus ,Plasma protein binding ,Microbiology ,Virus ,Cell Line ,Retrovirus ,Viral Envelope Proteins ,Lectins ,Virology ,Animals ,Humans ,Lectins, C-Type ,Cells, Cultured ,chemistry.chemical_classification ,biology ,Cell adhesion molecule ,HIV ,Dendritic Cells ,Dendritic cell ,biology.organism_classification ,Virus-Cell Interactions ,Cell biology ,DC-SIGN ,Endothelial stem cell ,Solubility ,chemistry ,Insect Science ,biology.protein ,Endothelium, Vascular ,Glycoprotein ,Cell Adhesion Molecules ,Protein Binding - Abstract
DC-SIGN and DC-SIGNR are two closely related membrane-associated C-type lectins that bind human immunodeficiency virus (HIV) envelope glycoprotein with high affinity. Binding of HIV to cells expressing DC-SIGN or DC-SIGNR can enhance the efficiency of infection of cells coexpressing the specific HIV receptors. DC-SIGN is expressed on some dendritic cells, while DC-SIGNR is localized to certain endothelial cell populations, including hepatic sinusoidal endothelial cells. We found that soluble versions of the hepatitis C virus (HCV) E2 glycoprotein and retrovirus pseudotypes expressing chimeric forms of both HCV E1 and E2 glycoproteins bound efficiently to DC-SIGN and DC-SIGNR expressed on cell lines and primary human endothelial cells but not to other C-type lectins tested. Soluble E2 bound to immature and mature human monocyte-derived dendritic cells (MDDCs). Binding of E2 to immature MDDCs was dependent on DC-SIGN interactions, while binding to mature MDDCs was partly independent of DC-SIGN, suggesting that other cell surface molecules may mediate HCV glycoprotein interactions. HCV interactions with DC-SIGN and DC-SIGNR may contribute to the establishment or persistence of infection both by the capture and delivery of virus to the liver and by modulating dendritic cell function.
- Published
- 2003
36. Differential N-Linked Glycosylation of Human Immunodeficiency Virus and Ebola Virus Envelope Glycoproteins Modulates Interactions with DC-SIGN and DC-SIGNR
- Author
-
Graham Simmons, George Lin, Frédéric Baribaud, Drew Weissman, Stefan Pöhlmann, Paul Bates, Beth S. Haggarty, George J. Leslie, James A. Hoxie, Houping Ni, and Robert W. Doms
- Subjects
Glycosylation ,viruses ,Immunology ,Receptors, Cell Surface ,Viral transformation ,medicine.disease_cause ,Microbiology ,Virus ,Cell Line ,VP40 ,Viral Envelope Proteins ,Viral envelope ,Polysaccharides ,Virology ,Murine leukemia virus ,medicine ,Humans ,Lectins, C-Type ,Ebola virus ,biology ,HIV ,Simian immunodeficiency virus ,Ebolavirus ,biology.organism_classification ,Virus-Cell Interactions ,DC-SIGN ,Insect Science ,biology.protein ,Cell Adhesion Molecules - Abstract
The C-type lectins DC-SIGN and DC-SIGNR [collectively referred to as DC-SIGN(R)] bind and transmit human immunodeficiency virus (HIV) and simian immunodeficiency virus to T cells via the viral envelope glycoprotein (Env). Other viruses containing heavily glycosylated glycoproteins (GPs) fail to interact with DC-SIGN(R), suggesting some degree of specificity in this interaction. We show here that DC-SIGN(R) selectively interact with HIV Env and Ebola virus GPs containing more high-mannose than complex carbohydrate structures. Modulation of N -glycans on Env or GP through production of viruses in different primary cells or in the presence of the mannosidase I inhibitor deoxymannojirimycin dramatically affected DC-SIGN(R) infectivity enhancement. Further, murine leukemia virus, which typically does not interact efficiently with DC-SIGN(R), could do so when produced in the presence of deoxymannojirimycin. We predict that other viruses containing GPs with a large proportion of high-mannose N -glycans will efficiently interact with DC-SIGN(R), whereas those with solely complex N -glycans will not. Thus, the virus-producing cell type is an important factor in dictating both N -glycan status and virus interactions with DC-SIGN(R), which may impact virus tropism and transmissibility in vivo.
- Published
- 2003
37. HIV-1 entry inhibitors: new targets, novel therapies
- Author
-
Theodore C. Pierson and Robert W. Doms
- Subjects
Receptors, CXCR4 ,Anti-HIV Agents ,business.industry ,Immunology ,Human immunodeficiency virus (HIV) ,Gene Products, env ,HIV Infections ,Receptors, Cell Surface ,medicine.disease_cause ,Virology ,Virus ,Drug Design ,HIV-1 ,medicine ,Animals ,Humans ,Immunology and Allergy ,Lectins, C-Type ,Receptors, Chemokine ,business ,Cell Adhesion Molecules - Published
- 2003
38. Truncation of the Cytoplasmic Domain Induces Exposure of Conserved Regions in the Ectodomain of Human Immunodeficiency Virus Type 1 Envelope Protein
- Author
-
Terri G. Edwards, Robert W. Doms, Jacqueline D. Reeves, Stéphanie Wyss, James A. Hoxie, Susan Zolla-Pazner, and Frédéric Baribaud
- Subjects
CD4-Positive T-Lymphocytes ,Protein Conformation ,viruses ,Protein subunit ,Molecular Sequence Data ,Immunology ,HIV Antibodies ,HIV Envelope Protein gp120 ,Biology ,Gp41 ,Membrane Fusion ,Microbiology ,Cell Line ,Frameshift mutation ,Conserved sequence ,Protein structure ,Neutralization Tests ,Virology ,Humans ,Amino Acid Sequence ,Frameshift Mutation ,Peptide sequence ,Conserved Sequence ,Antibodies, Monoclonal ,virus diseases ,Molecular biology ,HIV Envelope Protein gp41 ,Protein Structure, Tertiary ,Transmembrane domain ,Ectodomain ,Insect Science ,HIV-1 ,Pathogenesis and Immunity - Abstract
We have described a CD4-independent variant of HXBc2, termed 8x, that binds directly to CXCR4 and mediates CD4-independent virus infection. Determinants for CD4 independence map to residues in the V3 and V4-C4 domains together with a single nucleotide deletion in the transmembrane domain which introduces a frameshift (FS) at position 706. This FS results in a truncated cytoplasmic domain of 27 amino acids. We demonstrate here that while introduction of the 8x FS mutation into heterologous R5, X4, or R5X4 Env proteins did not impart CD4 independence, it did affect the conformation of the gp120 surface subunit, exposing highly conserved domains involved in both coreceptor and CD4 binding. In addition, antigenic changes in the gp41 ectodomain were also observed, consistent with the idea that the effects of cytoplasmic domain truncation must in some way be transmitted to the external gp120 subunit. Truncation of gp41 also resulted in the marked neutralization sensitivity of all Env proteins tested to human immunodeficiency virus-positive human sera and monoclonal antibodies directed against the CD4 or coreceptor-binding sites. These results demonstrate a structural interdependence between the cytoplasmic domain of gp41 and the ectodomain of the Env protein. They also may help explain why the length of the gp41 cytoplasmic domain is retained in vivo and may provide a way to genetically trigger the exposure of neutralization determinants in heterologous Env proteins that may prove useful for vaccine development.
- Published
- 2002
39. cisExpression of DC-SIGN Allows for More Efficient Entry of Human and Simian Immunodeficiency Viruses via CD4 and a Coreceptor
- Author
-
Elizabeth J. Soilleux, Nicholas Coleman, Ernest L. Levroney, Karen B. Flummerfelt, William J. Swiggard, Sarah S.W. Baik, George J. Leslie, Michael H. Malim, Robert W. Doms, Benhur Lee, and Una O'Doherty
- Subjects
Receptors, CXCR4 ,Receptors, CCR5 ,viruses ,Immunology ,Receptors, Cell Surface ,Biology ,Virus Replication ,Microbiology ,Virus ,Cell Line ,Viral envelope ,Viral entry ,Lectins ,Virology ,Humans ,Lectins, C-Type ,virus diseases ,HIV ,Lipid bilayer fusion ,Virus-Cell Interactions ,Cell biology ,DC-SIGN ,Viral replication ,Cell culture ,Insect Science ,CD4 Antigens ,biology.protein ,Tissue tropism ,Simian Immunodeficiency Virus ,Cell Adhesion Molecules - Abstract
Enveloped viral entry is mediated by interactions between cell surface receptor(s) and the viral envelope (Env) embedded in the virion lipid bilayer. These interactions trigger the requisite conformational changes in the viral Env that eventually lead to fusion between the viral and host cell membranes and delivery of the viral genome into the target cell. Human immunodeficiency virus type 1 (HIV-1) has evolved to use the CD4-coreceptor complex to trigger the conformational events leading to membrane fusion (reviewed in reference 8). In addition to entry receptors, attachment receptors have been described that can modulate the efficiency of entry mediated by the CD4-coreceptor complex (reviewed in reference 37). For example, heparan sulfate proteoglycans (21, 24, 29) and LFA-1 (12) have been reported to interact with viral Env or virion-associated adhesion molecules such as ICAM-1 in a manner that enhances the viral entry process. However, the majority of these interactions are low affinity in nature, having binding constants of 500 nM or greater (36, 37). Unique among these attachment molecules is the calcium-dependent lectin DC-SIGN, which binds to monomeric HIV-1 gp120 with a greater affinity than CD4 (Kd, 1.4 nM versus 4 to 5 nM for CD4) (6). The binding of DC-SIGN to HIV Env is carbohydrate dependent and is most effectively competed off by mannan (6, 13, 27). DC-SIGN is a type II integral membrane protein originally cloned from a placental cDNA library as a gp120 binding protein (6). It is highly expressed on dendritic cells (DCs) and is largely responsible for HIV-1 attachment to this cell type (13, 14). A homolog of DC-SIGN, termed “DC-SIGNR/L-SIGN,” is expressed on some types of endothelial cells and also serves as a virus attachment factor (3, 28, 33). Virus bound to DC-SIGN-positive cells can be transmitted to cells expressing CD4 and coreceptor, resulting in efficient virus infection in trans (13, 27). DC-SIGN on DCs may serve as a conduit for the transfer of HIV-1 from the submucosa to permissive T cells in secondary lymphoid organs (13, 35). We have shown that DC-SIGN also binds HIV-2 and SIV Envs and thus can be considered a universal attachment factor for primate lentiviruses (27). Despite initial reports that DC-SIGN expression is restricted to DCs, we have found that DC-SIGN is expressed on CD4+ macrophages in the placenta and lung (34; E. Soilleux, L. S. Morris, G. Leslie et al., submitted for publication). The presence of such a high-affinity attachment molecule on permissive cells in vivo prompted us to examine the consequences of DC-SIGN expression on the efficiency of viral entry. We found that expression of DC-SIGN in cis with CD4 and coreceptor allowed for more efficient entry of HIV and SIV. The ability of DC-SIGN to facilitate infection in cis was most apparent when either CD4 or coreceptor was limiting. In some cases, DC-SIGN expression allowed infection of cells via CD4 and an alternate coreceptor (STRL33) that is otherwise used inefficiently (30). In addition, some T-cell lines engineered to express DC-SIGN required up to 100-fold less of the viral inoculum in order to establish a productive infection. The in vivo significance of this cis-enhancement effect was supported by confocal microscopy data indicating that DC-SIGN was expressed and colocalized with CD4 and CCR5 on primary alveolar macrophages. Thus, DC-SIGN expression or upregulation in vivo can potentially expand viral tropism by allowing viruses to infect cells with limiting amounts of CD4 or coreceptor or by more efficient use of alternative coreceptors.
- Published
- 2001
40. DC-SIGN and DC-SIGNR: helping hands for HIV
- Author
-
Frédéric Baribaud, Robert W. Doms, and Stefan Pöhlmann
- Subjects
biology ,Transmission (medicine) ,Cell adhesion molecule ,Immunology ,Intercellular adhesion molecule ,medicine.disease ,Virology ,Virus ,Cell biology ,DC-SIGN ,Viral entry ,biology.protein ,medicine ,Immunology and Allergy ,Receptor ,Immunodeficiency - Abstract
The ability of dendritic cells (DCs) to promote HIV infection of T cells efficiently has been linked to the C-type lectin DC-specific intercellular adhesion molecule (ICAM)-grabbing nonintegrin (DC-SIGN). DC-SIGN and its homolog DC-SIGN-related (DC-SIGNR) capture and transmit human and simian immunodeficiency viruses to a wide variety of receptor-positive cells. The expression patterns of DC-SIGN and DC-SIGNR suggest that they might play roles in both horizontal and vertical transmission, as well as dissemination of virus within the host. In vivo experiments are required to prove these hypotheses and might pave the way for the development of new inhibitors of viral entry.
- Published
- 2001
41. CD4-Independent Use of Rhesus CCR5 by Human Immunodeficiency Virus Type 2 Implicates an Electrostatic Interaction between the CCR5 N Terminus and the gp120 C4 Domain
- Author
-
Beth S. Haggarty, Robert W. Doms, James A. Hoxie, George Lin, and Benhur Lee
- Subjects
Receptors, CCR5 ,Arginine ,viruses ,Molecular Sequence Data ,Static Electricity ,Immunology ,Lysine ,HIV Envelope Protein gp120 ,Biology ,Membrane Fusion ,Microbiology ,Chemokine receptor ,Viral entry ,Virology ,Aspartic acid ,Animals ,Humans ,Amino Acid Sequence ,Asparagine ,CXC chemokine receptors ,chemistry.chemical_classification ,virus diseases ,Macaca mulatta ,Virus-Cell Interactions ,Amino acid ,Biochemistry ,chemistry ,Insect Science ,CD4 Antigens ,HIV-2 ,Tyrosine - Abstract
Envelope glycoproteins (Envs) of human immunodeficiency virus type 2 (HIV-2) are frequently able to use chemokine receptors, CXCR4 or CCR5, in the absence of CD4. However, while these Envs are commonly dual-tropic, no isolate has been described to date that is CD4 independent on both CXCR4 and CCR5. In this report we show that a variant of HIV-2/NIHz, termed HIV-2/vcp, previously shown to utilize CXCR4 without CD4, is also CD4 independent on rhesus (rh) CCR5, but requires CD4 to fuse with human (hu) CCR5. The critical determinant for this effect was an acidic amino acid at position 13 in the CCR5 N terminus, which is an asparagine in huCCR5 and an aspartic acid in rhCCR5. Transferring the huCCR5 N terminus with an N13D substitution to CCR2b or CXCR2 was sufficient to render these heterologous chemokine receptors permissive for CD4-independent fusion. Chimeric Envs between HIV-2/vcp and a CD4-dependent clone of HIV-2/NIHz as well as site-directed Env mutations implicated a positively charged amino acid (lysine or arginine) at position 427 in the C4 region of the HIV-2/vcp env gene product (VCP) gp120 as a key determinant for this phenotype. Because CD4-independent use of CCR5 mapped to a negatively charged amino acid in the CCR5 N terminus and a positively charged amino acid in the gp120 C4 domain, an electrostatic interaction between these residues or domains is likely. Although not required for CD4-dependent fusion, this interaction may serve to increase the binding affinity of Env and CCR5 and/or to facilitate subsequent conformational changes that are required for fusion. Because the structural requirements for chemokine receptor use by HIV are likely to be more stringent in the absence of CD4, CD4-independent viruses should be particularly useful in dissecting molecular events that are critical for viral entry.
- Published
- 2001
42. Placental expression of DC-SIGN may mediate intrauterine vertical transmission of HIV
- Author
-
Elizabeth J. Soilleux, Nicholas Coleman, Stefan Pöhlmann, Lesley S. Morris, Benhur Lee, Robert W. Doms, and John Trowsdale
- Subjects
CD86 ,Transplacental transmission ,Trophoblast ,Dendritic cell ,Biology ,Virology ,Pathology and Forensic Medicine ,DC-SIGN ,Chemokine receptor ,medicine.anatomical_structure ,Antigen ,Hofbauer cell ,medicine ,biology.protein - Abstract
Mechanisms of transplacental transmission of human immunodeficiency virus (HIV) are poorly understood. DC-SIGN is a C-type lectin able to bind HIV gp120 with high affinity, mediating HIV adsorption to the surface of dendritic cells for up to several days. Via this mechanism, DC-SIGN significantly enhances the infection of CD4(+) co-receptor (CCR5 or CXCR4)(+) T lymphocytes in trans. In this study, DC-SIGN-specific serum was developed to investigate the cell type responsible for the high level of DC-SIGN RNA expression previously observed in the placenta. DC-SIGN expression was shown on CD68(+) HLA-II(+) CD14(low) S100(+/-) CD83(-) CD86(-) cmrf-44(-) villous cells consistent with Hofbauer cells and also on CD68(+) HLA-II(+) CD14(high) S100(-) CD83(-) CD86(-) cmrf-44(-) decidual macrophages. The DC-SIGN(+) Hofbauer cells co-express CD4 and the chemokine receptors, CCR5 and CXCR4, observations which may account for the ability of these cells to become infected with HIV. These fetal DC-SIGN(+) cells are separated by only a layer of trophoblast from both DC-SIGN(+) maternal cells and maternal blood, potential sources of HIV in infected mothers. Previous studies have suggested that this trophoblast layer is frequently breached during pregnancy. It is therefore proposed that DC-SIGN may facilitate the transplacental transmission of HIV.
- Published
- 2001
43. Relationships between CD4 Independence, Neutralization Sensitivity, and Exposure of a CD4-Induced Epitope in a Human Immunodeficiency Virus Type 1 Envelope Protein
- Author
-
Trevor L. Hoffman, Celia C. LaBranche, Matthew Sharron, Stéphanie Wyss, Robert W. Doms, James A. Hoxie, Frédéric Baribaud, Terri G. Edwards, Josephine Romano, and Joshua Adkinson
- Subjects
Receptors, CXCR4 ,Glycosylation ,Protein Conformation ,Immunology ,HIV Envelope Protein gp120 ,Biology ,V3 loop ,Transfection ,Gp41 ,Quail ,Microbiology ,Epitope ,Neutralization ,Cell Line ,Frameshift mutation ,Cell Fusion ,Epitopes ,chemistry.chemical_compound ,Neutralization Tests ,Virology ,Animals ,Humans ,Binding site ,Binding Sites ,Mutagenesis ,Antibodies, Monoclonal ,Blood Proteins ,HIV Envelope Protein gp41 ,Virus-Cell Interactions ,chemistry ,Insect Science ,CD4 Antigens ,HIV-1 ,Mutagenesis, Site-Directed ,Viral Fusion Proteins - Abstract
A CD4-independent version of the X4 human immunodeficiency virus type 1 (HIV-1) HXBc2 envelope (Env) protein, termed 8x, mediates infection of CD4-negative, CXCR4-positive cells, binds directly to CXCR4 in the absence of CD4 due to constitutive exposure of a conserved coreceptor binding site in the gp120 subunit, and is more sensitive to antibody-mediated neutralization. To study the relationships between CD4 independence, neutralization sensitivity, and exposure of CD4-induced epitopes associated with the coreceptor binding site, we generated a large panel of Env mutants and chimeras between 8x and its CD4-dependent parent, HXBc2. We found that a frameshift mutation just proximal to the gp41 cytoplasmic domain in 8x Env was necessary but not sufficient for CD4 independence and led to increased exposure of the coreceptor binding site. In the presence of this altered cytoplasmic domain, single amino acid changes in either the 8x V3 (V320I) or V4/C4 (N386K) regions imparted CD4 independence, with other changes playing a modulatory role. The N386K mutation resulted in loss of an N-linked glycosylation site, but additional mutagenesis showed that it was the presence of a lysine rather than loss of the glycosylation site that contributed to CD4 independence. However, loss of the glycosylation site alone was sufficient to render Env neutralization sensitive, providing additional evidence that carbohydrate structures shield important neutralization determinants. Exposure of the CD4-induced epitope recognized by monoclonal antibody 17b and which overlaps the coreceptor binding site was highly sensitive to an R298K mutation at the base of the V3 loop and was often but not always associated with CD4 independence. Finally, while not all neutralization-sensitive Envs were CD4 independent, all CD4-independent Envs exhibited enhanced sensitivity to neutralization by HIV-1-positive human sera, indicating that the humoral immune response can exert strong selective pressure against the CD4-independent phenotype in vivo. Whether this can be used to advantage in designing more effective immunogens remains to be seen.
- Published
- 2001
44. DC-SIGN Interactions with Human Immunodeficiency Virus Type 1 and 2 and Simian Immunodeficiency Virus
- Author
-
Jan Münch, Kirsten Hiebenthal-Millow, Stefan Pöhlmann, Frank Kirchhoff, Benhur Lee, Melissa D. Sánchez, George J. Leslie, Robert W. Doms, and Frédéric Baribaud
- Subjects
Cell type ,Glycosylation ,Molecular Sequence Data ,Immunology ,Gene Expression ,Mutagenesis (molecular biology technique) ,Receptors, Cell Surface ,medicine.disease_cause ,Microbiology ,Virus ,Lectins ,Virology ,medicine ,Animals ,Humans ,Lectins, C-Type ,Trypsin ,Amino Acid Sequence ,Edetic Acid ,Immunodeficiency ,Cell Line, Transformed ,biology ,Cell adhesion molecule ,Cell Membrane ,Cell sorting ,Simian immunodeficiency virus ,medicine.disease ,Molecular biology ,Virus-Cell Interactions ,DC-SIGN ,Mutagenesis ,Insect Science ,HIV-2 ,HIV-1 ,biology.protein ,Receptors, Virus ,Simian Immunodeficiency Virus ,Cell Adhesion Molecules - Abstract
Dendritic cells (DCs) efficiently bind and transmit human immunodeficiency virus (HIV) to cocultured T cells and so may play an important role in HIV transmission. DC-SIGN, a novel C-type lectin that is expressed in DCs, has recently been shown to bind R5 HIV type 1 (HIV-1) strains and a laboratory-adapted X4 strain. To characterize the interaction of DC-SIGN with primate lentiviruses, we investigated the structural determinants of DC-SIGN required for virus binding and transmission to permissive cells. We constructed a panel of DC-SIGN mutants and established conditions which allowed comparable cell surface expression of all mutants. We found that R5, X4, and R5X4 HIV-1 isolates as well as simian immunodeficiency and HIV-2 strains bound to DC-SIGN and could be transmitted to CD4/coreceptor-positive cell types. DC-SIGN contains a single N-linked carbohydrate chain that is important for efficient cell surface expression but is not required for DC-SIGN-mediated virus binding and transmission. In contrast, C-terminal deletions removing either the lectin binding domain or the repeat region abrogated DC-SIGN function. Trypsin-EDTA treatment inhibited DC-SIGN mediated infection, indicating that virus was maintained at the surface of the DC-SIGN-expressing cells used in this study. Finally, quantitative fluorescence-activated cell sorting analysis of AU1-tagged DC-SIGN revealed that the efficiency of virus transmission was strongly affected by variations in DC-SIGN expression levels. Thus, variations in DC-SIGN expression levels on DCs could greatly affect the susceptibility of human individuals to HIV infection.
- Published
- 2001
45. HIV-1 Membrane Fusion
- Author
-
Robert W. Doms and John P. Moore
- Subjects
CD4-Positive T-Lymphocytes ,Receptors, CXCR4 ,Protein Conformation ,Orthomyxoviridae ,Human immunodeficiency virus (HIV) ,medicine.disease_cause ,Membrane Fusion ,Models, Biological ,Motion ,03 medical and health sciences ,Helix (Snails) ,medicine ,030304 developmental biology ,0303 health sciences ,biology ,030306 microbiology ,Comment ,Temperature ,Lysophosphatidylcholines ,Lipid bilayer fusion ,Cell Biology ,biology.organism_classification ,Virology ,HIV Envelope Protein gp41 ,3. Good health ,Immunology ,HIV-1 ,Thermodynamics ,Aids pandemic - Abstract
Many viral fusion proteins exhibit a six-helix bundle as a core structure. HIV Env-induced fusion was studied to resolve whether membrane merger was due to the transition into the bundle configuration or occurred after bundle formation. Suboptimal temperature was used to arrest fusion at an intermediate stage. When bundle formation was prevented by adding inhibitory peptides at this stage, membranes did not merge upon raising temperature. Inversely, when membrane merger was prevented by incorporating lysophosphatidylcholine (LPC) into cell membranes at the intermediate, the bundle did not form upon optimizing temperature. In the absence of LPC, the six-helix bundle did not form when the temperature of the intermediate was raised for times too short to promote fusion. Kinetic measures showed that after the temperature pulse, cells had not advanced further toward fusion. The latter results indicate that bundle formation is the rate-limiting step between the arrested intermediate and fusion. Electrical measures showed that the HIV Env-induced pore is initially large and grows rapidly. It is proposed that bundle formation and fusion are each contingent on the other and that movement of Env during its transition into the six-helix bundle directly induces the lipid rearrangements of membrane fusion. Because peptide inhibition showed that, at the intermediate stage, the heptad repeats of gp41 have become stably exposed, creation of the intermediate could be of importance in drug and/or vaccine development.
- Published
- 2000
46. Characterization and Epitope Mapping of Neutralizing Monoclonal Antibodies Produced by Immunization with Oligomeric Simian Immunodeficiency Virus Envelope Protein
- Author
-
Robert W. Doms, Ména Ahuja, James A. Hoxie, Kelly C. Baxter, Tina Sung, Aimee L. Edinger, and Beth S. Haggarty
- Subjects
Receptors, CCR5 ,CD4 antigen ,medicine.drug_class ,viruses ,Blotting, Western ,Molecular Sequence Data ,Immunology ,Enzyme-Linked Immunosorbent Assay ,HIV Envelope Protein gp120 ,V3 loop ,Biology ,Monoclonal antibody ,medicine.disease_cause ,Binding, Competitive ,Microbiology ,Epitope ,Neutralization ,Mice ,chemistry.chemical_compound ,Viral Envelope Proteins ,Virology ,Vaccines and Antiviral Agents ,medicine ,Animals ,Amino Acid Sequence ,Mice, Inbred BALB C ,Membrane Glycoproteins ,Antibodies, Monoclonal ,Gene Products, env ,virus diseases ,Simian immunodeficiency virus ,Flow Cytometry ,Molecular biology ,Epitope mapping ,chemistry ,Insect Science ,CD4 Antigens ,biology.protein ,Immunization ,Simian Immunodeficiency Virus ,Antibody ,Epitope Mapping - Abstract
In an attempt to generate broadly cross-reactive, neutralizing monoclonal antibodies (MAbs) to simian immunodeficiency virus (SIV), we compared two immunization protocols using different preparations of oligomeric SIV envelope (Env) glycoproteins. In the first protocol, mice were immunized with soluble gp140 (sgp140) from CP-MAC, a laboratory-adapted variant of SIVmacBK28. Hybridomas were screened by enzyme-linked immunosorbent assay, and a panel of 65 MAbs that recognized epitopes throughout the Env protein was generated. In general, these MAbs detected Env by Western blotting, were at least weakly positive in fluorescence-activated cell sorting (FACS) analysis of Env-expressing cells, and preferentially recognized monomeric Env protein. A subset of these antibodies directed toward the V1/V2 loop, the V3 loop, or nonlinear epitopes were capable of neutralizing CP-MAC, a closely related isolate (SIVmac1A11), and/or two more divergent strains (SIVsmΔB670 CL3 and SIVsm543-3E). In the second protocol, mice were immunized with unfixed CP-MAC-infected cells and MAbs were screened for the ability to inhibit cell-cell fusion. In contrast to MAbs generated against sgp140, the seven MAbs produced using this protocol did not react with Env by Western blotting and were strongly positive by FACS analysis, and several reacted preferentially with oligomeric Env. All seven MAbs potently neutralized SIVmac1A11, and several neutralized SIVsmΔB670 CL3 and/or SIVsm543-3E. MAbs that inhibited gp120 binding to CD4, CCR5, or both were identified in both groups. MAbs to the V3 loop and one MAb reactive with the V1/V2 loop interfered with CCR5 binding, indicating that these regions of Env play similar roles for SIV and human immunodeficiency virus. Remarkably, several of the MAbs generated against infected cells blocked CCR5 binding in a V3-independent manner, suggesting that they may recognize a region analogous to the conserved coreceptor binding site in gp120. Finally, all neutralizing MAbs blocked infection through the alternate coreceptor STRL33 much more efficiently than infection through CCR5, a finding that has important implications for SIV neutralization assays using CCR5-negative human T-cell lines.
- Published
- 2000
47. Simian Immunodeficiency Virus Utilizes Human and Sooty Mangabey but Not Rhesus Macaque STRL33 for Efficient Entry
- Author
-
Benhur Lee, George J. Leslie, Robert W. Doms, Stefan Pöhlmann, Silke Meister, Frank Kirchhoff, and Mandy Krumbiegel
- Subjects
DNA, Complementary ,Receptors, CCR5 ,Chemokine receptor CCR5 ,animal diseases ,viruses ,Molecular Sequence Data ,Immunology ,Simian ,medicine.disease_cause ,Macaque ,Microbiology ,Cell Line ,Receptors, G-Protein-Coupled ,Serine ,Cercocebus atys ,biology.animal ,Virology ,medicine ,Animals ,Humans ,Amino Acid Sequence ,Receptors, Cytokine ,Cell Line, Transformed ,Receptors, CXCR6 ,Binding Sites ,Base Sequence ,Sequence Homology, Amino Acid ,biology ,Genetic Variation ,virus diseases ,Simian immunodeficiency virus ,biology.organism_classification ,Macaca mulatta ,Virus-Cell Interactions ,Rhesus macaque ,Coreceptor activity ,Insect Science ,Sooty mangabey ,biology.protein ,Receptors, Virus ,Receptors, Chemokine ,Simian Immunodeficiency Virus - Abstract
It has been established that many simian immunodeficiency virus (SIV) isolates utilize the orphan receptors GPR15 and STRL33 about as efficiently as the chemokine receptor CCR5 for entry into target cells. Most studies were performed, however, with coreceptors of human origin. We found that SIV from captive rhesus macaques (SIVmac) can utilize both human and simian CCR5 and GPR15 with comparable efficiencies. Strikingly, however, only human STRL33 (huSTRL33), not rhesus macaque STRL33 (rhSTRL33), functioned efficiently as an entry cofactor for a variety of isolates of SIVmac and SIV from sooty mangabeys. A single amino acid substitution of S30R in huSTRL33 impaired coreceptor activity, and the reverse change in rhSTRL33 greatly increased coreceptor activity. In comparison, species-specific sequence variations in N-terminal tyrosines in STRL33 had only moderate effects on SIV entry. These results show that a serine residue located just outside of the cellular membrane in the N terminus of STRL33 is critical for SIV coreceptor function. Interestingly, STRL33 derived from sooty mangabeys, a natural host of SIV, also contained a serine at the corresponding position and was used efficiently as an entry cofactor. These results suggest that STRL33 is not a relevant coreceptor in the SIV/macaque model but may play a role in SIV replication and transmission in naturally infected sooty mangabeys.
- Published
- 2000
48. Use of a gp120 Binding Assay To Dissect the Requirements and Kinetics of Human Immunodeficiency Virus Fusion Events
- Author
-
Sarah S.W. Baik, Robert W. Doms, and Benjamin J. Doranz
- Subjects
Glycosylation ,Receptors, CCR5 ,Protein Conformation ,Recombinant Fusion Proteins ,viruses ,Protein subunit ,Immunology ,HIV Envelope Protein gp120 ,Biology ,Gp41 ,Membrane Fusion ,Microbiology ,Cell Line ,Protein structure ,Cricetinae ,Virology ,Chlorocebus aethiops ,Animals ,Humans ,Binding site ,Cell Line, Transformed ,chemistry.chemical_classification ,Temperature ,env Gene Products, Human Immunodeficiency Virus ,Gene Products, env ,virus diseases ,Lipid bilayer fusion ,Chemokine receptor binding ,Molecular biology ,Virus-Cell Interactions ,Culture Media ,Cell biology ,Kinetics ,chemistry ,Ectodomain ,Insect Science ,CD4 Antigens ,HIV-1 ,Glycoprotein ,Oligopeptides ,HeLa Cells - Abstract
Binding of the extracellular subunit of human immunodeficiency type 1 (HIV-1) envelope (Env) glycoprotein (gp120) to CD4 triggers the induction or exposure of a highly conserved coreceptor binding site in gp120 that helps mediate membrane fusion. Characterizing the structural features involved in gp120-coreceptor binding and the conditions under which binding occurs is important for understanding the fusion process, the evolution of pathogenic strains in vivo, the identification of novel anti-HIV compounds, and the development of HIV vaccines that utilize triggered structures of Env. Here we use the kinetics of interaction between CCR5 and gp120 to understand temporal and structural changes that occur during viral fusion. Using saturation binding and homologous competition analysis, we estimated the K d of interaction between CCR5 and gp120 from the macrophage tropic HIV-1 strain JRFL to be 4 nM. Unlike Env-mediated fusion, gp120 binding to CCR5 did not require divalent cations or elevated temperatures. Binding was not significantly affected by the pH of binding, G-protein coupling of CCR5, or partial gp120 deglycosylation. Oligomeric, uncleaved JRFL gp140 failed to bind CCR5 despite its ability to bind CD4 and monoclonal antibody 17b, suggesting that the uncleaved ectodomain of gp41 interferes with full exposure of the chemokine receptor binding site. Exposure of the chemokine receptor binding site on gp120 could be induced rapidly by CD4, but exposure of this site was lost upon CD4 dissociation from gp120, indicating that the conformational changes in gp120 induced by CD4 binding are fully reversible. The functional gp120-soluble CD4 complex was remarkably stable over time and temperature ranges, offering the possibility that complexes in which the highly conserved coreceptor binding site in gp120 is exposed can be used for vaccine development.
- Published
- 1999
49. Determinants of CD4 Independence for a Human Immunodeficiency Virus Type 1 Variant Map outside Regions Required for Coreceptor Specificity
- Author
-
Terri G. Edwards, Trevor L. Hoffman, James A. Hoxie, Celia C. LaBranche, Thomas J. Matthews, Beth S. Haggarty, Josephine Romano, and Robert W. Doms
- Subjects
Models, Molecular ,Receptors, CXCR4 ,Receptors, CCR5 ,Protein Conformation ,Chemokine receptor CCR5 ,viruses ,Molecular Sequence Data ,Immunology ,Gene Expression ,C-C chemokine receptor type 7 ,C-C chemokine receptor type 6 ,HIV Envelope Protein gp120 ,V3 loop ,medicine.disease_cause ,Microbiology ,Chemokine receptor ,Viral envelope ,Virology ,Tumor Cells, Cultured ,medicine ,Humans ,Amino Acid Sequence ,Cloning, Molecular ,Genetics ,Binding Sites ,Base Sequence ,biology ,Chromosome Mapping ,Genetic Variation ,virus diseases ,Sequence Analysis, DNA ,Chemokine receptor binding ,Simian immunodeficiency virus ,Peptide Fragments ,Virus-Cell Interactions ,Insect Science ,CD4 Antigens ,DNA, Viral ,HIV-1 ,biology.protein - Abstract
Although infection by human immunodeficiency virus (HIV) typically requires an interaction between the viral envelope glycoprotein (Env), CD4, and a chemokine receptor, CD4-independent isolates of HIV and simian immunodeficiency virus have been described. The structural basis and underlying mechanisms for this phenotype are unknown. We have derived a variant of HIV-1/IIIB, termed IIIBx, that acquired the ability to utilize CXCR4 without CD4. This virus infected CD4-negative T and B cells and fused with murine 3T3 cells that expressed human CXCR4 alone. A functional IIIBx env clone exhibited several mutations compared to the CD4-dependent HXBc2 env , including the striking loss of five glycosylation sites. By constructing env chimeras with HXBc2, the determinants for CD4 independence were shown to map outside the V1/V2 and V3 hypervariable loops, which determine chemokine receptor specificity, and at least partly within an area on the gp120 core that has been implicated in forming a conserved chemokine receptor binding site. We also identified a point mutation in the C4 domain that could render the IIIBx env clone completely CD4 dependent. Mutations in the transmembrane protein (TM) were also required for CD4 independence. Remarkably, when the V3 loop of a CCR5-tropic Env was substituted for the IIIBx Env, the resulting chimera was found to utilize CCR5 but remained CD4 independent. These findings show that Env determinants for chemokine receptor specificity are distinct from those that mediate CD4-independent use of that receptor for cell fusion and provide functional evidence for multiple steps in the interaction of Env with chemokine receptors. Combined with our observation that the conserved chemokine receptor binding site on gp120 is more exposed on the IIIBx gp120 (T. L. Hoffman, C. C. LaBranche, W. Zhang, G. Canziani, J. Robinson, I. Chaiken, J. A. Hoxie, and R. W. Doms, Proc. Natl. Acad. Sci. USA 96:6359–6364, 1999), the findings from this study suggest novel approaches to derive and design Envs with exposed chemokine receptor binding sites for vaccine purposes.
- Published
- 1999
50. Functional Dissection of CCR5 Coreceptor Function through the Use of CD4-Independent Simian Immunodeficiency Virus Strains
- Author
-
Kevin J. Kunstman, Marc Parmentier, Robert W. Doms, Aimee L. Edinger, Steven M. Wolinsky, and Cédric Blanpain
- Subjects
Receptors, CCR5 ,Protein Conformation ,viruses ,Molecular Sequence Data ,Immunology ,Mutant ,Biology ,medicine.disease_cause ,Microbiology ,Virus ,Viral Envelope Proteins ,Viral entry ,Virology ,medicine ,Animals ,Humans ,Amino Acid Sequence ,Receptor ,Cell Line, Transformed ,Aspartic Acid ,Binding Sites ,virus diseases ,Simian immunodeficiency virus ,Virus-Cell Interactions ,N-terminus ,Viral Receptor ,Insect Science ,CD4 Antigens ,Simian Immunodeficiency Virus ,Function (biology) - Abstract
With rare exceptions, all simian immunodeficiency virus (SIV) strains can use CCR5 as a coreceptor along with CD4 for viral infection. In addition, many SIV strains are capable of using CCR5 as a primary receptor to infect CD4-negative cells such as rhesus brain capillary endothelial cells. By using coupled fluorescence-activated cell sorter (FACS) and infection assays, we found that even very low levels of CCR5 expression could support CD4-independent virus infection. CD4-independent viruses represent valuable tools for finely dissecting interactions between Env and CCR5 which may otherwise be masked due to the stabilization of these contacts by Env-CD4 binding. Based on the ability of SIV Env to bind to and mediate infection of cells expressing CCR5 chimeras and mutants, we identified the N terminus of CCR5 as a critical domain for direct Env binding and for supporting CD4-independent virus infection. However, the activity of N-terminal domain CCR5 mutants could be rescued by the presence of CD4, indicating that other regions of CCR5 are important for post-binding events that lead to viral entry. Rhesus CCR5 supported CD4-independent infection and direct Env binding more efficiently than did human CCR5 due to a single amino acid difference in the N terminus. Interestingly, uncleaved, oligomeric SIV Env protein bound to both CD4 and CCR5 less efficiently than did monomeric gp120. Finally, several mutations present in chronically infected monkey populations are shown to decrease the ability of CCR5 to serve as a primary viral receptor for the SIV isolates examined.
- Published
- 1999
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.